WO1999035243A2 - Extension of cellular lifespan, methods and reagents - Google Patents
Extension of cellular lifespan, methods and reagents Download PDFInfo
- Publication number
- WO1999035243A2 WO1999035243A2 PCT/US1999/000682 US9900682W WO9935243A2 WO 1999035243 A2 WO1999035243 A2 WO 1999035243A2 US 9900682 W US9900682 W US 9900682W WO 9935243 A2 WO9935243 A2 WO 9935243A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- cells
- telomerase
- agent
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- linear chromosomes of eukaryotic cells offer the biological advantages of rapid recombination, assortment, and genetic diversification.
- linear DNA is inherently more unstable than circular forms.
- the eukaryotic chromosome has evolved to include a DNA-protein structure, the telomere, which caps chromosome ends and protects them from degradation and end-to-end fusion (Blackburn (1984) Annu Rev Biochem 53:163- 194; Blackburn (1991) Nature 350:569-573; Zakian (1995) Science 270:1601-1607).
- telomeres The DNA component of telomeres consists of tandem repeats of guanine-rich sequences tha re essential for telomere function (Blackburn, supra; Zakian, supra). These repeats are replicated by conventional DNA polymerases and by a specialized enzyme, telomerase (Greider (1995) "Telomerase Biochemistry and Regulation” In: Telomeres. E.H. Blackburn and C.W. Greider, Eds. Cold Spring Harbor Press, Cold Spring Harbor, NY, pp.35-68), first identified in the ciliate Tetrahymena (Greider and Blackburn (1985) Cell 43:405-413).
- telomerase enzyme is essential for complete replication of telomeric DNA because the cellular DNA-dependent DNA polymerases ar unable to replicate the ultimate ends of the telomeres due to their requirement for a 5' RNA primer and their unidirectional mode of synthesis. Removal of the most terminal RNA primer following priming of DNA synthesis leaves a gap that cannot be replicated by these polymerases (Olovnikov (1971) Dokl. Akad. Nauk SSSR 201 :1496-1499; Watson (1972) Nat New Biol 239:197-201).
- telomerase surmounts this problem by do novo addition of single-stranded telomeric DNA to the ends of chromosomes (Greider and Blackburn (1985) supra: Greider and Blackburn (1989) Nature 337:331-337; Yu, et al. (1990) Nature 344:126-132; Greider (1995) supra).
- the telomerase enzymes that have been charcterized to date are RNA-dependent DNA polymerases that synthesize the telomeric DNA repeats by using an RNA template that exists as a subunit of the telomerase holoenzyme (Greider (1995), supra).
- telomeres The genes specifying the RNA subunits of telomerases have been cloned from a wide variety of species, including humans (Feng, et al. (1995) Science 269:1236-1241; Greider (1995), supra), and have been shown in several instances to be essential for telomerase function in vivo (Yu, et al. supra; Yu and Blackburn (1991) Cell 67:823-832; Singer and Gottschling (1994) Science 266:404-409; Cohn and Blackburn (1995) Science 269:396-400; McEachern and Blackburn (1995) Nature 376:403- 409). In addition, three proteins have been identified to date that rae associated with telomerase activity.
- P80 and p95 were purified from the ciliate Tetrahymena (Collins, et al. (1995) Cell 81:677-686), and the gene encoding a mammalian homolog of p80, TPl/TLPl, has also been cloned (Harrington, et al. (1997) Science 275:973-977; Nakayama, et al. (1997) CeU 88:875- 884). The specific mechanism by which these proteins participate in telomerase function has not been defined.
- telomere maintenance in yeast was identified as a gene required for telomere maintenance in yeast (Lendvay, et al. (1996) Genetics 144:1399-1412) and is essential for telomerase activity (Counter, et al. supra; Lingner, et al. supra).
- telomere shortening leads to progressive telomere shortening as cells pass through successive cycles of replication (Yu, et al. supra; Singer and Gottschling supra; McEachern and Blackburn supra; Lendvay, et al. supra; Counter, et al. supra; Lingner, et al. supra). This loss of telomeric DNA is ultimately lethal if it is not overcome.
- yeast cell lineages that lack telomerase activity have a lifespan dictated by the lenths of their telomeres.
- telomerase activity is readily detectable in germline cells and in certain stem cell compartments.
- enzyme activity is not dtectable in most somatic cell lineages (Harley, et al. (1994) Cold Spring Harbor Svmp. Quant. Biol. 59:307-315; Kim, et al. (1994) Science 266:2011-2015; Broccoli, et al. (1995) PNAS USA 92:9082-9086: Counter, et al. (1995) Blood 85:2315-2320; Hiyama, et al. (1995) J Immunol 155:3711-3715).
- telomeres of most types of human somatic cells shorten with increasing organismic age and with repeated passaging in culture, similar to the situation seen in protozoan and yeast cells that have been deprived experimentally of a functional telomerase enzyme (Harley, et al. (1990) Nature 345:458-460; Hastie, et al. (1990) Nature 346:866-868).
- telomerase enzyme Hastie, et al. (1990) Nature 346:866-868.
- the proliferation of cultured human cells will halt at a point termed senescence (Hayflick and Moorhead (1961) Exp Cell Res 25:585-621; Goldstein (1990) Science 249:1129-1133), apparently before the telomeres of these cells have become critically short.
- telomere shortening continues until a subsequent point is reached that is termed crisis, where telomeres have become extremely short (Counter, et al. (1992) EMBO J 11 :1921-1929; Counter, et al. (1994a) J Virol 68:3410-3414; Shay, et al. (1993) Oncogene 8:1407-1413; Klingehutz, et al. (1994)).
- telomere dysfunction is characterized by karyotypic instability, particularly the types of instability observed in chromosomes lacking functional telomeres, and by significant levels of cell death (Sack (1981) In Vitro 17:1-19).
- the crisis phenotype is pronounced of that observed in yeast and Tetrahymena cells in which telomerase function hasbeen experimentally perturbed.
- telomere-negative human cells like that of their yeast and ciliate counterparts, is ultimately limited by the length of telomeres.
- the immortal cells that escape crisis are characterized by readily detectable levels of telomerase activity and by stable telomeres (Counter, et al. (1992) supra: Counter, et al.
- telomere length of the lifespan of cell lineages Activation of telomerase also appears to be a major step in the progression of human cancers. Unlike normal human cells, cancer cells can be established as permanent cell lines and thus are presumed to have undergone immportalization during the process of tumorigenesis.
- telomerase activity is readily detected in the great majority of human tumor smaples analyzed to date (Counter, et al. (1994b) PNAS USA 91 :2900-2904; Kim, et al. 1994 supra): Shay and Bacchetti (1997) Eur J Cancer 33:787-791).
- telomere shortening serves as an important antineoplastic mechanism used by the body to block the expansion of pre- cancerous cell clones.
- tumor cells transcend the crisis barrier and emerge as immortalized cell populations by activating previously unexpressed telomerase, enabling them to restore and maintain the integrity of their telomeres (Counter, et al. (1992) supra: Counter, et al. (1994a) supra; Harley, et al. (1994) supra).
- telomere-associated protein TP1/TLP1 does not reflect the level of telomerase activity (Harrington, et al. supra; Nakayama, et al. supra). It is also clear that the levels of the human telomerase RNA component, hTR, cannot completely explain the regulation of telomerase activity. Although the levels of hTR and its mouse counterpart, mTR, increase with tumor progression (Feng, et al. (1995) Science 269:1236-1241; Blasco, et al. (1996) Nat Genet 12:200-204; Broccoli, et al.
- telomere-negative cells and tissues can be significantly higher in telomerase-negative cells and tissues than in telomerase-positive cancer cells (Avilion, et al. (1996) Cancer Res 56:645-650; Bestilny, et al. (1996) Cancer Res 56:3796-3802; Blasco, et al. supra).
- telomere levels increase 100- to 2000-fold during the immortalization of huma n cells
- the level of hTR message increases, at most, two-fold (Avilion, et al. supra). Therefore, depression of the hTR and TP1 subunits cannot easily be invoked to explain the appearance of telomerase activity in the great majority of human tumor samples. Thus far, the rate-limiting step in telomerase activation has remained elusive.
- One aspect of the present invention relates to methods and reagents for extending the lifespan, e.g., the number of mitotic divisions, of a cell.
- the subject method relies on the activation of a telomerase activity, such as by ectopic expression of the telomerase catalytic subunit EST2, or a bioactive fragment thereof, or the ectopic expression of myc, or a bioactive fragment thereof, or by contacting the cell with an agent (such as a small organic molecule) which activates expression of EST2 or myc or relieves an inhibitory signal (antagonism) of myc.
- an agent such as a small organic molecule
- ectopic expression it is meant that a cell is caused to express, e.g., by expression of a heterologous or endogenous gene or by transcellular uptake of a protein or inhibition of degradation of the EST2 or myc protein, a higher than normal level of EST2 or myc than the cell normally would for the particular starting phenotype.
- the subject method is useful both in vivo, ex vivo and in situ. Exemplary uses include, merely to illustrate, the extension of stem cell or progenitor cell cultures or implants, the extension of skin or other epithelial cell cultures or grafts, the expansion of mesenchymal cell cultures or grafts, and the expansion of chondrocyte or osteocyte cultures or grafts.
- Exemplary stem and progenitor cells which can be extended by the subject method include neuronal, hematopoietic, epithelial, pancreatic, hepatic, chondrocytic and osteocytic stem and progenitor cells.
- the subject method can be used for wound healing and other tissue repair, as well as cosemetic uses. It can be applied for prolonging the lifespan of a culture of normal cells or tissue being used to secrete therapeutic or other commercially significant proteins and products.
- the practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are described in the literature.
- HEST2 encodes a human homolog of Est2p and pi 23. Alignment of the predicted amino acid sequence of HEST2 with the yeast Est2p and Euplotes pi 23 homologs. Amino residues within shaded and closed blocks are indentical between at least two proteins. Indentical amino acids within the RT motifs are in closed boxes, an example of a telomerase- specific motif in an outlined shaded box, and all identical amino acids in shaded boxes. RT motifs are extended in some cases to include other adjacent invariant or conserved amino acids. The sequence of the expressed tag AA281296 is underlined.
- FIG. 1 Alignment of RT motifs 1-6 of telomerase subunits HEST2, pi 23 and Est2p with S Cerevisiae group II intron-encoded RTs a2-Sc and al-Sc.
- Amino acids that are invariant among the telomerases and the RT consensus are in shaded boxes. Open boxes identify highly conserved residues unique to either telomerases or to nontelomerase RTs. Astericks denote amino acids essential for polymerase catalytic function.
- FIG. 3 Myc activation of telomerase in HMEC cells.
- Primary HMEC cells at passage 12 were infected with empty vector (lanes 1-5), E6 (lanes 6-10), c-myc (lanes 11-15) or cdc25A (lanes 16-20) viruses.
- Two breast cancer cell lines BT549 (lanes 21-25) and T47D (lanes 26-30) were included for comparison.
- the cells were lysed and TRAP assays were performed using extract corresponding to 10,000 cells (lanes 2, 6, 7, 11,12, 17, 21, 22, 26 and 27), 1,000 cells (lanes 3, 8, 13, 18, 23 and 28), 100 cells (lanes 4, 9, 14, 19, 24 and 29) or 10 cells (lanes 5, 10, 15, 20, 25 and 30).
- telomerase activity was shown to be sensitive to RNase by the addition of RNase A prior to the telomerase assay ("-", without RNase A; "+”, with RNase A).
- lanes labelled "Mix” lanes labelled "Mix” (lanes 1 and 16) are assays containing lysate from 10,000 of the indicated cells mixed with lysate from 10,000 positive (c-» ⁇ yc-expressing) cells .
- Figure 4. Myc activaton of telomerase in IMR90 fibroblasts. IMR90 cells at passage 14 were infected with empty vector (lanes 1-5), c-myc (lanes 6-10) and E6 (lanes 11-15) viruses. HT1080 cells (lanes 15-20) were included for comparison.
- TRAP assays contained 10,000 cells (lanes 2, 6, 7, 12, 16 and 17), 1,000 cells (lanes 3, 8, 13 and 18), 100 cells (lanes 4, 9, 14 and 19) or 10 cells (lanes 5, 10, 15 and 20). Telomerase activity was shown to be sensitive to RNase by the addition of RNase A prior to extention reaction ("-", without RNase A; "+”, with RNase A). "Mix” lanes (1 and 11) are assays containing lysate from 10,000 of the indicated cells mixed with lysate from 10,000 positive (c-/wyoexpressing) cells.
- E6 increases c-myc protein level in HMEC.
- FIG. 6 Extention of telomere length and cellular lifespan by telomerase activation.
- A. Total RNA was prepared from normal HMEC and from HMEC that had been infected with a myc retrovirus. hEST2 transcript was visualized in equal quantities of RNA (10 ⁇ g) using a probe derived from the hEST2 cDNA.
- TRAP assays were performed using lysate equivalent to 10,000 cells (lanes 2, 6, 7, 12, 16 andl7), 1,000 cells (lanes 3, 8, 13 and 18), 100 cells (lanes 4, 9, 14 and 19) or 10 cells (lanes 5, 10, 15 and 20). Telomerase activity was shown to be sensitive to RNase by the addition of RNase A prior to assay ("-", without RNase A; "+”, with RNase A). To rule out the presence of inhibitors in apparently negative lysates, lanes labelled "Mix" (lanes 1 and 16) are assays containing lysate from 10,000 of the indicated cells mixed with lysate from 10,000 positive (HT1080) cells. C.
- Genomic DNA from early passage HMEC (passage 12, lane 1), late passage HMEC (passage 22, lane 2), HMEC/hEST2 (cells infected at passage 12 with hEST2 and subsequently cultured for 10 additional passages, lane 3) and HMEC/vector (cells infected at passage 12 with empty vector and subsequently cultured for 10 additional passages, lane 4) were digested with Rsa I and Hinf
- HMEC cells were transduced at passage 12 with either empty vector, c-Myc or hEST2 retroviruses (as indicated). These cells were continuously subcultured at a density of 4-5x10 5 cells per 100 cm 2 once per week. After 12 passages following transduction, vector-infected cells could no longer be subcultured at this frequency and adopted a classic senescent phenotype. In contrast, cells expressing myc and hEST2 continue to proliferate and showed a virtual absence of sensescent cells in the population.
- TTAGGG P-labled human telomeric sequence
- FIG. 6 Illustrates a MarxII vector including the coding sequence for hEST2.
- the long terminal repeats include, though not shown, recombinase sites such that, upon treatment of a cell in which the MarxII-hEST2 vector is integrated, the proviral vector including the hEST2 coding sequence is excised.
- Replicative senescence is dependent upon cumulative cell divisions and not chronologic or metabolic time, indicating that proliferation is limited by a "mitotic clock” (Dell'Orco et al. (1973) Exp. Cell Res. 77:356; Hadey et al. (1978) J. Cell. Phvsiol. 97:509).
- the reduction in proliferative capacity of cells from old donors and patients with premature aging syndromes (Martin et al. (1970) Lab. Invest 23:86; Schneider et al. (1976) PNAS 73:3584; Schneider et al. (1972) Proc. Soc. Exp. Biol. Med. 141:1092; Elmore et al.
- telomere loss is thought to control entry into senescence.
- Human telomeres consist of repeats of the sequence TTAGGG/CCCTAA at chromosome ends; these repeats are synthesized by the ribonucleoprotein enzyme telomerase. Telomerase is active in germline cells and, in humans, telomeres in these cells are maintained at about 15 kilobase pairs (kbp). In contrast, telomerase is not expressed in most human somatic tissues, and telomere length is significantly shorter.
- the telomere hypothesis of cellular aging proposes that cells become senescent when progressive telomere shortening during each division produces a threshold telomere length.
- the human telomerase reverse transcriptase subunit (hTRT) has been cloned. See
- telomere activity can be reconstituted by transient expression of hTRT in normal human diploid cells, which express the template RNA component of telomerase (hTR) but do not express hTRT. See, for example, Wang et al. (1998) Genes Dev 12:1769; and Weinrich et al., (1997) Nature Genet. 17:498. This provided the opportunity to manipulate telomere length and test the hypothesis that telomere shortening causes cellular senescence.
- telomere loss in the absence of telomerase is the intrinsic timing mechanism that controls the number of cell divisions prior to senescence.
- the long-term effects of exogenous telomerase expression on telomere maintenance and the life-span of these cells remain to be determined in studies of longer duration.
- telomere homeostasis is likely to result from a balance of lengthening and shortening activities. Very low levels of telomerase activity are apparently insufficient to prevent telomere shortening. This is consistent with the observation that stem cells have low but detectable telomerase activity, yet continue to exhibit shortening of their telomeres throughout life. Thus, a threshold level of telomerase activity is likely required for life-span extension.
- Cellular senescence is believed to contribute to multiple conditions in the elderly that could in principle be remedied by cell life-span extension in situ. Examples include atrophy of the skin through loss of extracellular matrix homeostasis in dermal fibroblasts; age-related macular degeneration caused by accumulation of lipofuscin and downregulation of a neuronal survival factor in RPE cells; and atherosclerosis caused by loss of proliferative capacity and overexpression of hypertensive and thrombotic factors in endothelial cells.
- Extended life-span cells also have potential applications ex vivo. Cloned normal diploid cells could replace established tumor cell lines in studies of biochemical and physiological aspects of growth and differentiation; long-lived normal human cells could be used for the production of normal or engineered biotechnology products; and expanded populations of normal or genetically engineered rejuvenated cells could be used for autologous or allogeneic cell and gene therapy.
- the ability to extend cellular life-span, while maintaining the diploid status, growth characteristics, and gene expression pattern typical of young normal cells has important implications for biological research, the pharmaceutical industry, and medicine.
- One aspect of the present invention relates to methods and reagents for extending the life- span, e.g., the number of mitotic divisions, of a cell.
- the cells are isolated in culture for at least a portion of the treatment.
- the invention provides a method for increasing the proliferative capacity of metazoan cells, preferably mammalian cells, and more preferably normal mammalian cells, by contacting the cell with an agent that activates telomerase activity in cell.
- the subject method relies on the ectopic expression of the telomerase catalytic subunit EST2, or a bioactive fragment thereof.
- ectopic expression it is meant that a cell is caused to express, e.g., by expression of a heterologous or endogenous gene or by transcellular uptake of a protein, a higher than normal level of EST2 than the cell normally would for the particular starting phenotype.
- the subject method can be carried out by the ectopic expression of an activator of telomerase activity (collectively herein "telomerase activator”) such as a myc gene product of a papillomavirus E6 protein.
- telomerase activator an activator of telomerase activity
- myc gene product of a papillomavirus E6 protein a myc gene product of a papillomavirus E6 protein.
- expression of the gene in the host cell is inducible (or otherwise conditionally regulated) and/or the genetic construct including the gene can be readily removed from thehost cell.
- the subject method can be carried out by contacting the cell with an agent that inhibits degradation (ubiquitin-dependent or independent) of the EST2 protein or telomerase activator in order to increase the cellular half-life of the protein.
- the method can utilize an agent which inhibits ubiquitination of to increase the cellular half-life of the protein.
- the method can utilize an agent which inhibits ubiquitination of myc and thereby increases the cellular concentration of myc.
- such agents are small, organic molecules, e.g., having molecular weights of less than 5000 amu (more preferably less than 1000 amu), and which are membrane permeant.
- cellular prolifeartive capacity can be incrased by contacting the cell with an agent, e.g. a small molecule, which relieves or otherwise inhibits a signal which antagonizes /wye-induced activation of telomerase activity.
- agents can be used which disrupt protein-protein interactions involved in inhibition of myc activity by, e.g., mad- max heterodimers.
- the subject method is useful both in vivo, ex vivo and in situ.
- Exemplary uses include, merely to illustrate, the extension of stem cell or progenitor cell cultures or implants, the extension of skin or other epithelial cell cultures or grafts, the expansion of mesenchymal cell cultures or grafts, and the expansion of chondrocyte or osteocyte cultures or grafts.
- Exemplary stem and progenitor cells which can be extended by the subject method include neuronal, hematopoietic, pancreatic, and hepatic stem and progenitor cells.
- telomerase activity rather than constitutive activation.
- the vector can be configured so as to be excisable from the cell.
- cells can be treated ex vivo with a vector encoding EST2 of a telomerase activator, and prior to implantation, the vector can be excised to inhibit further recombinant expression of the construct in vivo.
- the vector can be excised so as to have little to no heterologous nucleic acid sequences in the host cell.
- Another aspect of the present invention relates to in vitro preparations of cells which have been treated by the subject method. Such cell compositions can be used, e.g., to generate a medicament for transplantation to an animal.
- fusion protein is art recognized and refer to a chimeric protein which is at least initially expressed as single chain protein comprised of amino acid sequences derived from two or more different proteins, e.g., the fusion protein is a gene product of a fusion gene.
- fusion gene refers to a nucleic acid in which two or more genes are fused resulting in a single open reading frame for coding two or more proteins that as a result of this fusion are joined by one or more peptide bonds.
- nucleic acid refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
- RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides.
- gene refers to a nucleic acid comprising an open reading frame encoding a polypeptide, including both exonic and
- a gene can be in the form of a DNA construct which is transcribed or an RNA construct which is directly translatable.
- An exemplary recombinant gene encoding a subject EST2 protein is represented by SEQ. ID NO: 1.
- transfection means the introduction of a heterologous nucleic acid, e.g., an expression vector, into a recipient cell by nucleic acid-mediated gene transfer.
- Transformation refers to a process in which a cell's genotype is changed as a result of the cellular uptake of exogenous DNA or RNA, and, for example, the transformed cell expresses a recombinant form of an EST2 or myc polypeptide.
- “Expression vector” refers to a replicable nucelic acid construct used to express a gene which encodes the desired protein and which includes a transcriptional unit comprising an assembly of (1) genetic element(s) having a regulatory role in gene expression, for example, promoters, operators, or enhancers, operatively linked to (2) a sequence encoding a desired protein (e.g. an EST2 or myc protein), and (3) as necessary, appropriate transcription and translation initiation and termination sequences.
- a desired protein e.g. an EST2 or myc protein
- the choice of promoter and other regulatory elements generally varies according to the intended host cell.
- expression vectors of utility in recombinant techniques are often in the form of "plasmids" which refer to circular double stranded DNA loops which, in their vector form are not bound to the chromosome.
- plasmid and "vector” are used interchangeably as the plasmid is the most commonly used form of vector.
- the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.
- regulatory elements controlling transcription or translation can be generally derived from mammalian, microbial, viral or insect genes The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated.
- Vectors derived from viruses, such as retroviruses, adenoviruses, and the like, may be employed.
- Transcriptional regulatory sequence is a generic term used throughout the specification to refer to nucleic acid sequences, such as initiation signals, enhancers, and promoters and the like which induce or control transcription of protein coding sequences with which they are operably linked.
- transcription of the EST2 or other telomerase activator gene is under the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of one of the naturally-occurring forms of a protein.
- tissue-specific promoter means a DNA sequence that serves as a promoter, i.e., regulates expression of a selected DNA sequence operably linked to the promoter, and which effects expression of the selected DNA sequence in specific cells of a tissue, such as cells of a urogenital origin, e.g. renal cells, or cells of a neural origin, e.g. neuronal cells.
- tissue-specific promoter a DNA sequence that serves as a promoter, i.e., regulates expression of a selected DNA sequence operably linked to the promoter, and which effects expression of the selected DNA sequence in specific cells of a tissue, such as cells of a urogenital origin, e.g. renal cells, or cells of a neural origin, e.g. neuronal cells.
- the term also covers so-called “leaky” promoters, which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well.
- telomeres refer to catalytic subunits of telomerase, preferably of a mammalian telomerase, and even more preferably of a human telomerase.
- exemplary EST2 proteins are encoded by the nucleic acid of SEQ ID NO:l, or by a nucleic acid which hybridizes thereto.
- the EST2 proteins useful in the subject method can be at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even at least 95% identical to the human EST2 of SEQ ID NO:2, or a fragment thereof which reconsitutes a telomerase elongation enzyme in a host cell (such as a human cell).
- a host cell such as a human cell.
- a variety of different techniques are available in the art for assessing the activity of a particular EST2 polypeptide, e.g., which may vary in sequence and/or length relative to SEQ ID NO: 1.
- telomerase-activating therapeutic agent refers to any agent which can be used to activation of telomerase activity in a cell, e.g., a mammalian cell.
- a mammalian cell e.g., a mammalian cell.
- it includes expression vectors encoding EST2, myc, E6 or the like, formulations of such polypeptides, small molecule activators of expression of an endogenous telomerase activator gene, inhibitors of degradation of a telomerase activator, to name but a few.
- EST2 therapeutic agent refers to any telomerase-activating therapeutic agent which can be used to cause ectopic expression of an EST2 polypeptide in a cell.
- EST2 expression vectors for example, it includes EST2 expression vectors, formulations of EST2 polypeptides, and small molecule activators of expression of an endogenous EST2 gene, to name but a few.
- the term “derepresses myc” refers to the ability of an agent to overcome an antagonism of myc, e.g., it may prevent mad/max inactivation of myc and thereby activates myc.
- progenitor cell refers to an undifferentiated cell which is capable of proliferation and giving rise to more progenitor cells having the ability to generate a large number of mother cells that can in turn give rise to differentiated, or differentiable daughter cells.
- progenitor cell is also intended to encompass a cell which is sometimes referred to in the art as a "stem cell”.
- progenitor cell refers to a generalized mother cell whose descendants (progeny) specialize, often in different directions, by differentiation, e.g., by acquiring completely individual characters, as occurs in progressive diversification of embryonic cells and tissues.
- the term “substantially pure”, with respect to progenitor cells refers to a population of progenitor cells that is at least about 75%, preferably at least about 85%, more preferably at least about 90%, and most preferably at least about 95% pure, with respect to progenitor cells making up a total cell population.
- the term “substantially pure” refers to a population of progenitor cell of the present invention that contain fewer than about 20%, more preferably fewer than about 10%, most preferably fewer than about 5%, of lineage committed cells in the original unamplified and isolated population prior to subsequent culturing and amplification.
- composition refers to a preparation of cells, which preparation may include, in addition to the cells, non-cellular components such as cell culture media, e.g. proteins, amino acids, nucleic acids, nucleotides, co-enzyme, anti-oxidants, metals and the like.
- non-cellular components such as cell culture media, e.g. proteins, amino acids, nucleic acids, nucleotides, co-enzyme, anti-oxidants, metals and the like.
- the cellular composition can have components which do not affect the growth or viability of the cellular component, but which are used to provide the cells in a particular format, e.g., as polymeric matrix for encapsulation or a pharmaceutical preparation.
- animal refers to mammals, preferably mammals such as humans.
- a "patient” or “subject” to be treated by the method of the invention can mean either a human or non-human animal.
- the subject involves the administration of an expression vector encoding an EST2 polypeptide or other telomerase activator polypeptide.
- the predicted 127 kDa protein shares extensive sequence similarity with the entire sequences of the Euplotes and yeast telomerase subunits (Figure 1) and extends beyond the amino and carboxyl termini of these proteins.
- a BLAST search reveals that the probabilities of these smilarieites occurring by chance are 1.3 x 10 " ' 8 and 3 x 10 "13 , respectively.
- the probability of similarity between the yeast and Euplotes telomerases in a protein BLAST search is 6.9 x 10 "6 .
- hEST2 is a member of the reverse transcriptase (RT) family of enzymes ( Figures 1 and 2). Seven conserved sequence motifs, which define the polymerase domains of these enzymes, are shared among the otherwise highly divergent RT family (Poch et al. (1989) EMBO J 8:3867-3874; Xiong and Eickbush (1990) EMBO J 9:3353-3362). PI 23 and Est2p share six of these motifs with, most prominently, the a2-Sc enzyme, an RT that is encoded within the second intron of the yeast COX1 gene (Kennell et al. (1993) Cell 133-146).
- RT reverse transcriptase
- telomerase catalytic subunit like its yeast and ciliate counterparts, belongs to the RT superfamily of enzymes.
- Exemplary human EST coding sequence and protein for use in the subject method is provided at GenBank accession AF018167, AF043739 and AF015950.
- Exemplary EST constructs are also decribed in PCT application WO98/14593 and Ulaner et al. (1998) Cancer
- the EST construct includes an EST coding sequence which hybridizes under stringent conditions to SEQ ID No: 1, or a coding sequence set forth in GenBank accession AF018167, AF043739 or AF015950.
- the EST coding sequence can encode an EST protein, or fragment thereof which retains a telomerase activity, which is is at least, for example, 60, 70 , 80, 85, 90 , 95 or 98 percent identical with a sequence of SEQ ID No. 2 or GenBank accession AF018167, AF043739 and AF015950, or identical with one of the enumerated sequences.
- telomerase activation can be caused by ectopic expression of a myc protein, e.g., c-myc.
- a myc protein e.g., c-myc.
- An exemplary human myc coding sequence is provided at the SWISS-PROT locus MYC_HUMAN, accession P01106.
- the myc construct includes an myc coding sequence which hybridizes under stringent conditions to a coding sequence set forth in SWISS-PROT locus MYC_HUMAN, accession P01106.
- the myc coding sequence can encode a myc protein, or fragment thereof which retains the ability to activate a telomerase activity, which is is at least, for example, 60, 70 , 80, 85, 90 , 95 or 98 percent identical with the protein sequence set forth in SWISS-PROT locus MYC_HUMAN, accession P01106, or identical thereto.
- telomerase activation is accomplished by expression of a papillomavirus E6 protein, preferably an E6 protein from a human papillomavirus (HPV), and more preferably an E6 protein from a high risk HPV (e.g., HPV-16 or -18). It may desirable to use an E6 protein which has been mutated so as to be incapable of effecting p53 degradation.
- the E6 construct includes an E6 coding sequence which hybridizes under stringent conditions to a coding sequence set forth in EMBL: locus A06324, accession A06324.
- the E6 coding sequence can encode an E6 protein, or fragment thereof which retains the ability to activate a telomerase activity, which is is at least, for example, 60, 70 , 80, 85, 90 , 95 or 98 percent identical with the protein sequence set forth in EMBL: locus A06324, accession A06324, or identical thereto
- expression constructs of the subject polypeptides may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively transfecting cells in vitro or in vivo with a recombinant gene.
- Approaches include insertion of the subject EST2 or telomerase activator gene in viral vectors including recombinant retroviruses, adeno virus, adeno-associated virus, and herpes simplex virus- 1, or recombinant bacterial or eukaryotic plasmids.
- Viral vectors can be used to transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g.
- a preferred approach for introduction of nucleic acid encoding a telomerase activator into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding the gene product.
- a viral vector containing nucleic acid e.g. a cDNA
- Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid.
- molecules encoded within the viral vector e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.
- Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous genes in vivo, particularly into humans.
- retroviruses provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.
- a major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population.
- the development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) Blood 76:271).
- recombinant retrovirus can be constructed in which part of the retroviral coding sequence (gag, pol, env) has been replaced by nucleic acid encoding, e.g., an EST2 or myc polypeptide, rendering the retrovirus replication defective.
- the replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology. Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9J0-9J4 and other standard laboratory manuals.
- retroviruses examples include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art.
- suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include ⁇ Crip, ⁇ Cre, ⁇ 2 and ⁇ Am.
- Retroviruses have been used to introduce a variety of genes into many different cell types, including neural cells, epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Nati. Acad. Sci.
- retroviral vectors as a gene delivery system for the subject telomerase activator proteins, it is important to note that a prerequisite for the successful infection of target cells by most retroviruses, and therefore of stable introduction of the recombinant gene, is that the target cells must be dividing. In general, this requirement will not be a hindrance to use of retroviral vectors to deliver the subject gene constructs.
- retroviral-based vectors by modifying the viral packaging proteins on the surface of the viral particle.
- strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for cell surface antigens to the viral env protein (Roux et al. (1989) PNAS 86:9079-9083; an et al. (1992) J. Gen Virol 73:3251-3255; and Goud et al.
- Virology 163:251-254 or coupling cell surface ligands to the viral env proteins (Neda et al. (1991) J Biol Chem 266:14143-14146). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the env protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g. single-chain antibody/env fusion proteins).
- This technique while useful to limit or otherwise direct the infection to certain tissue types, and can also be used to convert an ecotropic vector in to an amphotropic vector.
- use of retroviral gene delivery can be further enhanced by the use of tissue- or cell-specific transcriptional regulatory sequences which control expression of the recombinant gene of the retroviral vector.
- Another viral gene delivery system useful in the present invention utilitizes adenovirus- derived vectors.
- the genome of an adenovirus can be manipulated such that it encodes a gene product of interest, but is inactivate in terms of its ability to replicate in a normal lytic viral life cycle (see, for example, Berkner et al. (1988) BioTechniques 6:616; Rosenfeld et al. (1991) Science 252:431-434; and Rosenfeld et al. (1992) CeU 68:143-155).
- Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus are.
- Recombinant adeno viruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including endothelial cells (Lemarchand et al. (1992) Proc. Nati. Acad. Sci. USA 89:6482-6486), and smooth muscle cells (Quantin et al. (1992) Proc. Nati. Acad. Sci. USA 89:2581-2584).
- the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity.
- introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA).
- the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al., supra; Haj-Ahmand and Graham (1986) J. Virol. 57:267).
- adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral El and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al. (1979) Cell 16:683; Berkner et al., supra; and Graham et al. in Methods in Molecular Biology, E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127).
- Expression of the inserted gene can be under control of, for example, the El A promoter, the major late promoter (MLP) and associated leader sequences, the E3 promoter, or exogenously added promoter sequences.
- MLP major late promoter
- Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle.
- AAV vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb.
- An AAV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-3260 can be used to introduce DNA into cells.
- a variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example
- herpes virus vectors may provide a unique strategy for persistent expression of the subject telomerase activator proteins in cells of the central nervous system, such as neuronal stem cells, and ocular tissue (Pepose et al. (1994) Invest Ophthalmol Vis Sci 35:2662-2666)
- non-viral methods can also be employed to cause expression of a the subject proteins in the tissue of an animal.
- Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules.
- non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the gene by the targeted cell.
- Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.
- a gene encoding one of the subject proteins can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the target tissue (Mizuno et al. (1992) No Shinkei Geka 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075).
- lipofection of neuroglioma cells can be carried out using liposomes tagged with monoclonal antibodies against glioma-associated antigen (Mizuno et al. (1992) Neurol. Med. Chir. 32:873- 876).
- the gene delivery system comprises an antibody or cell surface ligand which is cross-linked with a gene binding agent such as poly-lysine (see, for example, PCT publications WO93/04701, WO92/22635, WO92/20316, WO92/19749, and
- the subject gene construct can be used to transfect hepatocytic cells in vivo using a soluble polynucleotide carrier comprising an asialoglycoprotein conjugated to a polycation, e.g. poly-lysine (see U.S. Patent 5,166,320).
- a soluble polynucleotide carrier comprising an asialoglycoprotein conjugated to a polycation, e.g. poly-lysine (see U.S. Patent 5,166,320).
- effective delivery of the subject nucleic acid constructs via receptor-mediated endocytosis can be improved using agents which enhance escape of the gene from the endosomal structures.
- whole adenovirus or fusogenic peptides of the influenza HA gene product can be used as part of the delivery system to induce efficient disruption of DNA-containing endosomes
- the present invention provides a method for increasing the proliferative capacity of cells, preferably normal cells, which method comprises delivering into the cell a gene construct which can selectively and reversibly activate telomerase activity in the cell.
- the coding sequence for the telomerase activator is provided as part of a vector which can be partially or completely excised from the host cell is an inducible manner.
- the vector can include:
- transposition elements for integration of the vector into chromosomal DNA of a eukaryotic host cell
- excision elements for removing, upon contact of the cell with an excision agent (which activates the excision element) all or at least the portion of an integrated form of the vector from chromosomal DNA in a manner which is results in loss-of- function of the heterologous telomerase activator.
- the excision elements can be provided in the vector so as flank at least the coding sequence of a telomerase activator, though they may flank only a portion of the coding sequence such that the sequence resulting after excision does not encode a functional activator, or they may flank a sufficient portion of a transcriptional regulatory sequence for the telomerase activator such that resulting construct does not express the telomerase activator.
- the exicision elements are disposed in the vector such that, upon excision of the integrated form of the vector, no or substantially no portion (e.g., less than 50 nucleotides) of the vector DNA is left in the chromosomal DNA of the host cell.
- the transposition elements are viral transposition elements, e.g, retroviral or lentiviral transposition elements, such as may be provided where the vector is a replication-deficient virus.
- the excision elements comprise enzyme-assisted site-specific integration sequences.
- the excision elements may include recombinase target sites, e.g., recombinase target sites for Cre recombinase, Flp recombinase, Pin recombinase, lamda integrase, Gin recombinase or R recombinase.
- the excision elements may also be restriction enzyme sites.
- the vector is a retroviral vector which recombinase sites which are located in the LTRs such that excision of a pro viral sequence occurs, e.g., the viral vector is completely, or nearly completely excised from the chromosomal DNA of the host cell.
- the vector can include such other elements as: transcriptional regulatory sequences for directing transcription of the coding sequence for the telemorase activator cnucleic; a packaging signal for packaging the vector in an infectious viral particle;
- Exemplary vectors of this type are descibed in the appended examples as well as PCT publication WO 98/12339.
- the cells can be treated ex vivo with the constructs.
- an agent such as a recombinase, which results in exicision of the vector from the genomic DNA of the host cell.
- the cells which are implanted are no longer genetically engineered.
- telomerase activation can also be generated by use of an expression system which is inducible because of the presence of an inducible transcriptional regulatory sequence controlling the expression of the coding sequence of the EST or telomerase activator.
- Inducible promoters arc promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g., the presence or absence of a nutrient or a change in temperature.
- the inducible promoter is preferably one which is regulated by a small molecule or other factor which is not endogenous to the host animal.
- Exemplary regulatable promoters include the dine responsive promoters, such as described in. for example. Gossen et al. (1992) PNAS 89:5547-5551; and Pescini et al., (1994) Biochem. Biophvs. Res. Comm. 202:1664-1667.
- the subject method utilizes the multimerization technology first pioneered by Schreiber and Crabtree. This technique permits the regulation of expression of an endogenous or heterologous gene, in this case a coding sequence for EST or a telomerase activator, by use of chimeric transcription factors which are dependent on small molecules "dimerizers" to assemble transcriptionally active complexes.
- telomere activation can be accomplished by use of conditionally active (or conditionally inactivable) forms of EST or of the telomerase activators.
- conditionally active or conditionally inactivable forms of EST or of the telomerase activators.
- temperature-sensitive mutants of telomerase or myc can be employed in the subject method.
- the ts mutant can be inactive at body temperature (the non-permissive temperature) and active at a lower or higher cell culture temperature.
- N-degron is an intracellular degradation signal whose essential determinant is a "destabilizing" N-terminal residue of a protein.
- a set of N-degrons containing different destabilizing residues is manifested as the N-end rule, which relates the in vivo half-life of a protein to the identity of its N-terminal residue.
- the N-degron consists of at least two determinants: a destabilizing N-terminal residue and a specific internal Lys residue (or residues) of a substrate.
- the Lys residue is the site of attachment of a multiubiquitin chain.
- Ubiquitin is a protein whose covalent conjugation to other proteins plays a role in a number of cellular processes, primarily through routes that involve protein degradation.
- exemplary heat-inducible N-degron modules which can be adapted for generating conditional mutants of EST, myc or other telomerase activators, see US Patents 5,705,387 and 5,538,862, and Dohmen et al. (1994) Science 263:1273-6.
- the multimerization technology referred to above can be used to generate small molecule inducible forms of EST or a telomerase activator.
- a first gene construct can be provided which encodes a fusion protein including a DNA binding domain (and optionally oligomerization domains) of myc and a ligand binding domain which binds to a small organic molecule, e.g., a domain which will bind to a dimerizing agent.
- a second gene construct is also provided, which construct encodes a fusion protein including an activation domain, e.g., a VP16 activation domain, and a ligand binding domain which will also bind the dimerizing agent when it is already bound to the first fusion protein.
- telomere binding protein Upon addition of the dimerizing agent, the fusion proteins associate, and activate transcription of genes which include myc responsive elements, which causes activation of telomerase activity.
- ectopic expression of EST2 or other telomerase activator can be by way of a "gene activation" construct which, by homologous recombination with a genomic sequence
- the gene activation construct can replace the endogenous promoter of an EST2 gene with a heterologous promoter, e.g., one which causes consitutive expression of the EST2 gene or which causes inducible expression of the gene under conditions different from the normal expression pattern of the gene.
- a vareity of different formats for the gene activation constructs are available. See, for example, the Transkaryotic Therapies, Inc PCT publications WO93/09222, WO95/31560, WO96/29411, WO95/31560 and WO94/12650.
- the nucleotide sequence used as the gene activation construct can be comprised of (1) DNA from some portion of the endogenous gene (exon sequence, intron sequence, promoter sequences, etc.) which direct recombination and (2) heterologous transcriptional regulatory sequence(s) which is to be operably linked to the coding sequence for the genomic gene upon recombination of the gene activation construct.
- the construct may further include a reporter gene to detect the presence of the knockout construct in the cell.
- the gene activation construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to provide the heterologous regulatory sequences in operative association with, e.g., the native EST2 gene.
- Such insertion occurs by homologous recombination, i.e., recombination regions of the activation construct that are homologous to the endogenous EST2 gene sequence hybridize to the genomic DNA and recombine with the genomic sequences so that the construct is incorporated into the corresponding position of the genomic DNA.
- recombination region or “targeting sequence” refer to a segment (i.e., a portion) of a gene activation construct having a sequence that is substantially identical to or substantially complementary to a genomic gene sequence, e.g., including 5' flanking sequences of the genomic gene, and can facilitate homologous recombination between the genomic sequence and the targeting transgene construct.
- replacement region refers to a portion of a activation construct which becomes integrated into an endogenous chromosomal location following homologous recombination between a recombination region and a genomic sequence.
- the heterologous regulatory sequences can include one or more of a variety elements, including: promoters (such as constitutive or inducible promoters), enhancers, negative regualtory elements, locus control regions, transcription factor binding sites, or combinations thereof.
- Promoters/enhancers which may be used to control the expression of the targeted gene in vivo include, but are not limited to, the cytomegalovirus (CMV) promoter/enhancer (Karasuyama et al., 1989, J. Exp. Med., 169:13), the human ⁇ -actin promoter (Gunning et al.
- CMV cytomegalovirus
- MMTV LTR mouse mammary tumor virus long terminal repeat
- MoLV LTR Moloney murine leukemia virus
- SV40 early or late region promoter Bosset et al. (1981) Nature 290:304-310; Templeton et al. (1984) Mol. Cell Biol. 4:817; and Sprague et al.
- the replacement region merely deletes a negative transcriptional control element of the native gene, e.g., to activate expression.
- membrane permeable drugs e.g., preferably small organic molecules
- membrane permeable drugs can be identified which activate the expression of an endogenous EST2 gene.
- a reporter gene is operably linked to the transcriptional regulatory seqence of the EST2 gene.
- the resulting cells can be used in a cell-based approach for identifying such compounds.
- RNA encoding EST2 myc or another telomerase activator can be introduced directly into the cell, e.g., from RNA generated by in vitro transciption.
- the RNA is preferably a modified polynucleotide which is resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases.
- Exemplary nucleic acid modifications which can be used to generate such RNA polynucleotides include phosphoramidate, phosphothioate and methylphosphonate analogs of nucleic acids (see also U.S. Patents 5,176,996; 5,264,564; and 5,256,775), or peptide nucleic acids (PNAs).
- the telomerase activator polypeptide can be contacted with a cell under conditions wherein the protein is taken up by the cell, e.g., internalized, without the need for recombinant expression in the cell.
- a variety of techniques have been developed for the transcytotic delivery of ectopically added proteins.
- the EST2 or myc protein is provided for transmucosal or transdermal delivery.
- penetrants appropriate to the barrier to be permeated are used in the formulation with the polypeptide.
- penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives.
- detergents may be used to facilitate permeation.
- Transmucosal administration may be through nasal sprays or using suppositories.
- the proteins of the invention are formulated into ointments, salves, gels, or creams as generally known in the art. For example, Chien et al. (1989) J. Pharm. Sci.
- USSN 5,459,127 describes the use of cationic lipids for intracellular delivery of biologically active molecules.
- USSN 5,190,762 describes methods of administering proteins to living skin cell.
- the polypeptide is provided as a chimeric polypeptide which includes a heterologous peptide sequence ("internalizing peptide") which drives the translocation of an extracellular form of a thereapeutic polypeptide sequence across a cell membrane in order to facilitate intracellular localization of the thereapeutic polypeptide.
- the therapeutic polypeptide sequence is one which is active intracellularly, such as a tumor suppressor polypeptide, transcription factor or the like.
- the internalizing peptide by itself, is capable of crossing a cellular membrane by, e.g., transcytosis, at a relatively high rate.
- the internalizing peptide is conjugated, e.g., as a fusion protein, to the telomerase activator polypeptide.
- the resulting chimeric polypeptide is transported into cells at a higher rate relative to the activator polypeptide alone to thereby provide an means for enhancing its introduction into cells to which it is applied, e.g., to enhance topical applications of the EST2 polypeptide.
- the internalizing peptide is derived from the drosopholia antepennepedia protein, or homologs thereof.
- the 60 amino acid long long homeodomain of the homeo-protein antepennepedia has been demonstrated to translocate through biological membranes and can facilitate the translocation of heterologous polypeptides to which it is couples. See for example Derossi et al. (1994) J Biol Chem 269:10444-10450; and Perez et al. (1992) J Cell Sci 102:717-722. Recently, it has been demonstrated that fragments as small as 16 amino acids long of this protein are sufficient to drive internalization. See Derossi et al. (1996) J Biol Chem 271 :18188-18193.
- the present invention contemplates a chimeric protein comprising at least one EST2 or myc polypeptide sequence and at least a portion of the antepennepedia protein (or homolog thereof) sufficient to increase the transmembrane transport of the chimeric protein, relative to the EST2 or myc polypeptide, by a statistically significant amount.
- HIV transactivator (TAT) protein Another example of an internalizing peptide is the HIV transactivator (TAT) protein. This protein appears to be divided into four domains (Kuppuswamy et al. (1989) Nucl. Acids Res. 17:3551-3561). Purified TAT protein is taken up by cells in tissue culture (Frankel and Pabo, (1989) Cell 55:1189-1193).
- peptides such as the fragment corresponding to residues 37 -62 of TAT, are rapidly taken up by cell in vitro (Green and Loewenstein, (1989) Cell 55:1 179-1188).
- the highly basic region mediates internalization and targeting of the internalizing moiety to the nucleus (Ruben et al., (1989) J. Virol. 63:1-8).
- Peptides or analogs that include a sequence present in the highly basic region such as CFITKALGISYGRKKRRQRRRPPQGS, are conjugated to EST2 or myc polypeptides to aid in internalization and targeting those proteins to the intracellular milleau.
- transcellular polypeptide can be generated to include a sufficient portion of mastoparan (T. Higashijima et al., (1990) J. Biol. Chem. 265:14176) to increase the transmembrane transport of the chimeric protein.
- hydrophilic polypeptides may be also be physiologically transported across the membrane barriers by coupling or conjugating the polypeptide to a transportable peptide which is capable of crossing the membrane by receptor-mediated transcytosis.
- Suitable internalizing peptides of this type can be generated using all or a portion of, e.g., a histone, insulin, transferrin, basic albumin, prolactin and insulin-like growth factor I (IGF-I), insulin-like growth factor II (IGF-II) or other growth factors.
- an insulin fragment showing affinity for the insulin receptor on capillary cells, and being less effective than insulin in blood sugar reduction, is capable of transmembrane transport by receptor-mediated transcytosis and can therefor serve as an internalizing peptide for the subject transcellular polypeptides.
- Preferred growth factor- derived internalizing peptides include EGF (epidermal growth factor)-derived peptides, such as CMHIESLDSYTC and CMYIEALDKYAC; TGF- beta (transforming growth factor beta )- derived peptides; peptides derived from PDGF (platelet-derived growth factor) or PDGF-2; peptides derived from IGF-I (insulin-like growth factor) or IGF-II; and FGF (fibroblast growth factor)-derived peptides.
- EGF epidermatitis
- translocating/internalizing peptides exhibits pH-dependent membrane binding.
- the internalizing peptide acquires the property of amphiphilicity, e.g., it has both hydrophobic and hydrophilic interfaces. More specifically, within a pH range of approximately 5.0-5.5, an internalizing peptide forms an alpha-helical, amphiphilic structure that facilitates insertion of the moiety into a target membrane.
- An alpha-helix-inducing acidic pH environment may be found, for example, in the low pH environment present within cellular endosomes.
- Such internalizing peptides can be used to facilitate transport of telomerase activator polypeptides, taken up by an endocytic mechanism, from endosomal compartments to the cytoplasm.
- a preferred pH-dependent membrane-binding internalizing peptide includes a high percentage of helix-forming residues, such as glutamate, methionine, alanine and leucine.
- a preferred internalizing peptide sequence includes ionizable residues having pKa's within the range of pH 5-7, so that a sufficient uncharged membrane-binding domain will be present within the peptide at pH 5 to allow insertion into the target cell membrane.
- a particularly preferred pH-dependent membrane-binding internalizing peptide in this regard is aal-aa2-aa3-EAALA(EALA)4-EALEALAA-amide, which represents a modification of the peptide sequence of Subbarao et al. (Biochemistry 26:2964. 1987).
- the first amino acid residue (aal) is preferably a unique residue, such as cysteine or lysine, that facilitates chemical conjugation of the internalizing peptide to a targeting protein conjugate.
- Amino acid residues 2-3 may be selected to modulate the affinity of the internalizing peptide for different membranes.
- the internalizing peptide will have the capacity to bind to membranes or patches of lipids having a negative surface charge. If residues 2-3 are neutral amino acids, the internalizing peptide will insert into neutral membranes.
- Still other preferred internalizing peptides include peptides of apo-lipoprotein A-l and B; peptide toxins, such as melittin, bombolittin, delta hemolysin and the pardaxins; antibiotic peptides, such as alamethicin; peptide hormones, such as calcitonin, corticotrophin releasing factor, beta endorphin, glucagon, parathyroid hormone, pancreatic polypeptide; and peptides corresponding to signal sequences of numerous secreted proteins.
- exemplary internalizing peptides may be modified through attachment of substituents that enhance the alpha-helical character of the internalizing peptide at acidic pH.
- Yet another class of internalizing peptides suitable for use within the present invention include hydrophobic domains that are "hidden” at physiological pH, but are exposed in the low pH environment of the target cell endosome. Upon pH-induced unfolding and exposure of the hydrophobic domain, the moiety binds to lipid bilayers and effects translocation of the covalently linked polypeptide into the cell cytoplasm.
- Such internalizing peptides may be modeled after sequences identified in, e.g., Pseudomonas exotoxin A, clathrin, or Diphtheria toxin.
- Pore-forming proteins or peptides may also serve as internalizing peptides herein. Pore-forming proteins or peptides may be obtained or derived from, for example, C9 complement protein, cytolytic T-cell molecules or NK-cell molecules. These moieties are capable of forming ring-like structures in membranes, thereby allowing transport of attached polypeptide through the membrane and into the cell interior.
- an internalizing peptide may be sufficient for translocation of the polypeptide, e.g. EST2 or myc, across cell membranes.
- translocation may be improved by attaching to the internalizing peptide a substrate for intracellular enzymes (i.e., an "accessory peptide").
- an accessory peptide be attached to a portion(s) of the internalizing peptide that protrudes through the cell membrane to the cytoplasmic face.
- the accessory peptide may be advantageously attached to one terminus of a translocating/internalizing moiety or anchoring peptide.
- An accessory moiety of the present invention may contain one or more amino acid residues.
- an accessory moiety may provide a substrate for cellular phosphorylation (for instance, the accessory peptide may contain a tyrosine residue).
- An exemplary accessory moiety in this regard would be a peptide substrate for N- myristoyl transferase, such as GNAAAARR (Eubanks et al., in: Peptides. Chemistry and Biology. Garland Marshall (ed.), ESCOM, Leiden, 1988, pp. 566-69)
- N- myristoyl transferase such as GNAAAARR (Eubanks et al., in: Peptides. Chemistry and Biology. Garland Marshall (ed.), ESCOM, Leiden, 1988, pp. 566-69)
- an internalizing, peptide would be attached to the C-terminus of the accessory peptide, since the N- terminal glycine is critical for the accessory moiety's activity.
- This hybrid peptide upon attachment to an EST2 or myc polypeptide at its C-terminus, is N-myristylated and further anchored to the target cell membrane, e.g., it serves to increase the local concentration of the polypeptide at the cell membrane.
- a phosphorylatable accessory peptide is first covalently attached to the C-terminus of an internalizing peptide and then incorporated into a fusion protein with an EST2 or myc polypeptide.
- the peptide component of the fusion protein intercalates into the target cell plasma membrane and, as a result, the accessory peptide is translocated across the membrane and protrudes into the cytoplasm of the target cell.
- the accessory peptide On the cytoplasmic side of the plasma membrane, the accessory peptide is phosphorylated by cellular kinases at neutral pH. Once phosphorylated, the accessory peptide acts to irreversibly anchor the fusion protein into the membrane.
- Suitable accessory peptides include peptides that are kinase substrates, peptides that possess a single positive charge, and peptides that contain sequences which are glycosylated by membrane-bound glycotransferases.
- Accessory peptides that are glycosylated by membrane- bound glycotransferases may include the sequence x-NLT-x, where "x" may be another peptide, an amino acid, coupling agent or hydrophobic molecule, for example.
- an accessory peptide can be used to enhance interaction of the telomerase activator polypeptide with the target cell.
- Exemplary accessory peptides in this regard include peptides derived from cell adhesion proteins containing the sequence "RGD", or peptides derived from laminin containing the sequence CDPGYIGSRC.
- Extracellular matrix glycoproteins such as fibronectin and laminin, bind to cell surfaces through receptor-mediated processes.
- a tripeptide sequence, RGD has been identified as necessary for binding to cell surface receptors. This sequence is present in fibronectin, vitronectin, C3bi of complement, von-Willebrand factor, EGF receptor, transforming growth factor beta , collagen type I, lambda receptor of E. coli, fibrinogen and Sindbis coat protein (E. Ruoslahti, Ann. Rev. Biochem.
- the internalizing and accessory peptides can each, independently, be added to an EST2 or myc polypeptide by either chemical cross-linking or in the form of a fusion protein.
- unstructured polypeptide linkers can be included between each of the peptide moieties.
- the internalization peptide will be sufficient to also direct export of the polypeptide.
- an accessory peptide such as an RGD sequence
- the secretion signal sequence is located at the extreme N-terminus, and is (optionally) flanked by a proteolytic site between the secretion signal and the rest of the fusion protein.
- an EST2 or myc polypeptide is engineered to include an integrin-binding RGD peptide/SV40 nuclear localization signal (see, for example Hart SL et al., 1994; J. Biol. Chem.,269: 12468- 12474), such as encoded by the nucleotide sequence provided in the Ndel-EcoRl fragment: catatgggtggctgccgtggcgatatgttcggttgcggtgcggtgctcctccaaaaaagaagagaaagagaag- gtagctggattc, which encodes the RGD/SV40 nucleotide sequence: MGGCRGDMFGCGAPP- KKKRKVAGF.
- RGD/SV40 nucleotide sequence MGGCRGDMFGCGAPP- KKKRKVAGF.
- the protein can be engineered with the HIV-1 tat(l-72) polypeptide, e.g., as provided by the Ndel-EcoRl fragmentcatatggagccagtagatcctagactagagccc- tggaagcatccaggaagtcagcctaaaactgcttgtaccaattgctattgtaaaaagtgttgctttcattgccaagtttgtttcataacaaaagcc cttggcaggaagaagcggagacagcgacgaaagacctcctcaaggcagtcagactcatcaagtttctctaagtagcaag gattc, which encodes the HIV-1 tat(l-72) peptide sequence: MEPVDPRLEPWKHPGSQPKT- ACTNCYCKKCCFHCQVCFIT
- the fusion protein includes the HSV-1 VP22 polypeptide (Elliott G., O'Hare P (1997) CeU, 88 ⁇ 223-233) provided by the Ndel-EcoRl fragment: cat atg ace tct cgc cgc tec gtg aag teg ggt ccg egg gag gtt ccg cgc gat gag tac gag gat ctg tac tac ace ccg tct tea ggt atg gcg agt ccc gat agt ccg cct gac ace tec cgc cgt ggc gcc eta cag aca cgc teg cgc cag agg ggc gag gtc cgttc gtc cag tac gac gag teg gat tat gcc etc tac
- the fusion protein includes the C-terminal domain of the VP22 protein from, e.g., the nucleotide sequence (Ndel-EcoRl fragment): cat atg gac gtc gac gcg gcc acg gcg act cga ggg cgt tct gcg gcg teg cgc cccc ace gag cga cct cga gcc cca gcc cgc tec get tct cgc cc aga egg ccc gtc gag gaa ttc which encodes the VP22 (C-terminal domain) peptide sequence:
- the subject method employs small, organic molecules, e.g., having a molecular weight of less than 5000 amu, more preferably less than 1000 amu, and even more preferably less than 500 amu.
- small, organic molecules e.g., having a molecular weight of less than 5000 amu, more preferably less than 1000 amu, and even more preferably less than 500 amu.
- such compounds are preferably membrane permeant, e.g., able to diffuse across the cell membrane into the host cell when added directly to culture cells or cells in whole blood.
- the intracellular level of I R 1 or a telomerase activator can be upregulated by inhibiting its natural turnover rate.
- inhibitors of ubiquitin-dependent or independent degradation of the protein can be used to cause ectopic expression of protein in the sense that the concentration of the protein in the cell can be artificially elevated.
- cellular prolifeartive capacity can be incrased by contacting the cell with an agent, e.g. a small molecule, which relieves or otherwise inhibits a signal which antagonizes myc-induced activation of telomerase activity.
- agents can be used which disrupt protein-protein interactions involved in inhibition of myc activity by, e.g., mad- max heterodimers.
- Another aspect of the invention provides a conjoint therapy wherein one or more other therapeutic agents are administered with the telomerase-activating therapeutic agent.
- Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
- the telomerase-activating therapeutic agent can be administered conjointly with a growth factors and other mitogenic agents.
- Mitogenic agent refers to any compound or composition, including peptides, proteins, and glycoproteins, which is capable of stimulating proliferation of a target cell population.
- the telomerase-activating therapeutic agent can be conjointly administered with a T-cell mitogenic agent such as lectins, e.g., concanavalin A or phytohemagglutinin.
- exemplary mitogenic agents include insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and certain of the transforming growth factors (TGFs).
- IGF insulin-like growth factor
- PDGF platelet-derived growth factor
- FGF fibroblast growth factor
- TGFs transforming growth factors
- the subject telomerase-activating therapeutic agent agent is co- administered with an agent that relieves "capping" inhibition of EST2 rescue.
- EST2 wiill neither extend telomere length nor lifespan in late-passage HMEC cells, and certain other cell lines such as fibroblasts.
- telomere binding proteins such as TRF (TTAGGG repeat binding factor) become abundant relevant to the telomeric sequences.
- TRF TTAGGG repeat binding factor
- Such relative overabundance of proteins to telomers may be the result of, for example, reduction in the number of telomeric sequences relative to a constant concentration of associated proteins, increased expression (or stability) of the associated proteins, or a combination thereof.
- the cells can be treated with an oligonucleotide which competes (e.g., as a decoy) with the telomeres for binding of the telomere binding proteins.
- an oligonucleotide which competes (e.g., as a decoy) with the telomeres for binding of the telomere binding proteins.
- a dominant negative mutant of a telomere binding protein can be introduced into the cell in order to inhibit the formation of inhibitory protein complexes with the telomeric sequences. See, for example, Bianchi et al. (1997) EMBO J 16:1785-94; Broccoli et al. (1997) Hum Mol Genet 6: 69-76; Smith et al.
- the agent can be an inhibitor of expression of a telomere binding proteins, such as antisense or a small molecule inhibitor of transcription of the gene.
- agents, particularly small molecules can be identified by their ability to directly inhibit the formation of telomeric complexes including telomere binding proteins.
- the present method can be used to increase the proliferative capacity of cells in vivo, in vitro and as part of an ex vivo protocol. While the method of the invention is applicable to any normal cell type, the method is preferably practiced using normal cells that express a low level of telomerase activity.
- the term "normal” refers to cells other than tumor cells, cancer calls, or transformed cells.
- An exemplary cell is an embryonic stem cells, such as disclosed in Thomson et al. (1998) Science 282:1145 and Shamblott et al. (1998) PNAS 95:13726.
- Especially preferred cells for use in the present method include embryonic, fetal, neonatal, and adult stem cells of any organ, and adult pluripotent hematopoietic stem cells.
- the cells are stem and/or progenitor cells. These include hematopoietic stem cells, e.g., which are derived from bone marrow, mobilized peripheral blood cells, or cord blood.
- the cells are progenitor cells for pancreatic or hepatic tissue, or other tissue deriving from the primative gut.
- the stem is a neuronal stem cell, such as neural crest which can be used to form neurons or smooth muscle cells.
- the cells are not stem or progenitor cells, e.g., they are committed cells, such as pancreatic ⁇ cells, smooth muscle cells (or other myocytic cells), fibroblasts, lymphocytic cells, e.g., B or T cells, osteocytes or chondrocytes, to name but a few.
- they are committed cells, such as pancreatic ⁇ cells, smooth muscle cells (or other myocytic cells), fibroblasts, lymphocytic cells, e.g., B or T cells, osteocytes or chondrocytes, to name but a few.
- the subject method can be used either in vivo or in vitro, the invention has particular application to the cultivation of cells ex vivo, and provides especially important benefits to therapeutic methods in which cells are cultured ex vivo and then reintroduced to a host.
- the subject method can be used to extend the proliferative capacity of cells which are harvested, or otherwise isolated in culture, which are to be transplanted to a patient.
- Such protocols can find use in bone marrow transplants wherein bone marrow, or isolated hematopoietic progenitor cells are treated according to the present invention, with the activation of telomerase and inactivation of Rb being reverted to the wild-type phenotype before, or shortly after, transplantation.
- the subject method can also be used to extend T cell life in HIV and Down's patients.
- tissue such as prosthetic devices, e.g., deriving from stem or committed cells.
- exemplary tissues include pancreatic, hepatic, neural, myocytic, cartilaginous and osseous tissue.
- hematopoietic cells refers to fully differentiated myeloid cells such as erythrocytes or red blood cells, megakaryocytes, monocytes, granulocytes, and eosinophils, as well as fully differentiated lymphoid cells such as B lymphocytes and T lymphocytes.
- a hematopoietic stem/progenitor cell includes the various hematopoietic precursor cells from which these differentiated cells develop, such as BFU-E (burst-forming units-erythroid), CFU-E (colony forming unit-erythroid), CFU-Meg (colony forming unit-megakaryocyte), CFU-GM (colony forming unit-granulocyte-monocyte), CFU-Eo (colony forming unit-eosinophil), and CFU-GEMM (colony forming unit-granulocyte- erythrocyte-megakaryocyte-monocyte) .
- BFU-E burst-forming units-erythroid
- CFU-E colony forming unit-erythroid
- CFU-Meg colony forming unit-megakaryocyte
- CFU-GM colony forming unit-granulocyte-monocyte
- CFU-Eo colony forming unit-eosinophil
- the subject method can be use to extend the lifespan of a pancreatic cells and pancreatic stem/progenitor cells.
- pancreatic progenitor cell refers to a cell which can differentiate into a cell of pancreatic lineage, e.g. a cell which can produce a hormone or enzyme normally produced by a pancreatic cell.
- a pancreatic progenitor cell may be caused to differentiate, at least partially, into ⁇ , ⁇ , ⁇ , or ⁇ islet cell, or a cell of exocrine fate.
- the pancreatic progenitor cells of the invention can also be cultured prior to administration to a subject under conditions which promote cell proliferation and differentiation. These conditions include culturing the cells to allow proliferation and confluence in vitro at which time the cells can be made to form pseudo islet-like aggregates or clusters and secrete insulin, glucagon, and somatostatin.
- the endocrine portion of the pancreas is composed of the islets of Langerhans.
- the islets of Langerhans appear as rounded clusters of cells embedded within the exocrine pancreas.
- the ⁇ cells constitute about 20% of the cells found in pancreatic islets and produce the hormone glucagon.
- Glucagon acts on several tissues to make energy available in the intervals between feeding.
- glucagon causes breakdown of glycogen and promotes gluconeogenesis from amino acid precursors.
- the ⁇ cells produce somatostatin which acts in the pancreas to inhibit glucagon release and to decrease pancreatic exocrine secretion.
- the hormone pancreatic polypeptide is produced in the ⁇ cells. This hormone inhibits pancreatic exocrine secretion of bicarbonate and enzymes, causes relaxation of the gallbladder, and decreases bile secretion.
- the most abundant cell in the islets, constituting 60-80% of the cells, is the ⁇ cell, which produces insulin. Insulin is known to cause the storage of excess nutrients arising during and shortly after feeding.
- the major target organs for insulin are the liver, muscle, and fat-organs specialized for storage of energy.
- the subject telomerase-activating therapeutic agents can be used to extend the lifespan of implanted pancreatic tissue, e.g., implanted ⁇ -islet cells.
- tissue-engineering approaches to treatment have focused on transplanting pancreatic islets, usually encapsulated in a membrane to avoid immune rejection.
- Many methods for encapsulating cells are known in the art.
- a source of ⁇ islet cells producing insulin is encapsulated in implantable hollow fibers. Such fibers can be pre-spun and subsequently loaded with the ⁇ islet cells (Aebischer et al. U.S. Patent No. 4,892,538; Aebischer et al. U.S. Patent No.
- the pancreatic cells can be treated by the subject method ex vivo, and/or treated by the subject method by subsequent delivery of an therapeutic to an animal in which the device is implanted.
- Such cells can be used for treatment of diabetes because they have the ability to differentiate into cells of pancreatic lineage, e.g., ⁇ islet cells.
- the pancreatic cells of the invention can be cultured in vitro under conditions which can further induce these cells to differentiate into mature pancreatic cells, or they can undergo differentiation in vivo once introduced into a subject.
- the subject method can be used to extend the life of normal pancreatic cells used to produce cultures for the production and purification of secreted factors.
- cultured cells can be provided as a source of insulin.
- exocrine cultures can be provided as a source for pancreatin.
- the subject method can be used to extend the life span of hepatic cells and hepatic stem cells.
- hepatic progenitor cell refers to a cell which can differentiate in a cell of hepatic lineage, such a liver parenchymal cell, e.g., a hepatocyte. Hepatocytes are some of the most versatile cells in the body. Hepatocytes have both endocrine and exocrine functions, and synthesize and accumulate certain substance, detoxify others, and secrete others to perform enzymatic, transport, or hormonal activities.
- liver cells include bile secretion, regulation of carbohydrate, lipid, and protein metabolism, storage of substances important in metabolism, degradation and secretion of hormones, and transformation and excretion of drugs and toxins.
- the subject method can be used to facilitate the long term culture of hepatic cells and hepatic progenitor cells either in vitro or subsequent to implantation.
- the subject method can be used to enhance the life of "feeder" cell layers for cell co-cultures.
- the subject method can be used to enhance large-scale cloning, e.g., of non-human animals, by enhancing the presence of actively dividing fetal fibroblasts for nuclear transfer.
- cloning e.g., of non-human animals
- the cell cycle stage of the donor cell affects the extent of development of the embryo after nuclear transfer.
- the recipient oocyte which is arrested in the second metaphase in meiosis
- the nuclear envelope breaks down and the chromosomes condense until the oocyte is activated.
- This condensation phase has been shown to cause chromosomal defects in donor cells that are undergoing DNA synthesis.
- Donor cells in the G j phase of the cell cycle (before DNA synthesis), however, condense normally and support a high rate of early development.
- the cell should not have ceased dividing (which is the case in G Q ) but be actively dividing, as an indication of a relatively undifferentiated state and for compatibility with the rapid cell divisions that occur during early embryo development.
- the cells should also be in G ] , either by artificially arresting the cell cycle or by choosing a cell type that has an inherently long Gl phase.
- the subject methods are also applicable to general cell culture techniques.
- the method can be used to increase the replicative capacity of hybrids between immortal and mortal human cells, such as hybrids between human B-lymphocytes and myeloma cells, e.g., to increase the replicative capacity of antibody producing human hybridomas.
- the subject method can be used to increase the replicative capacity of cells in culture which have been engineered to produce recombinant proteins.
- the subject method can permit the use of "normal" cells as the recombinant cell, so that problems which may occur with the use of immortal cells (such as differences in post-translation modifications) can be avoided, particularly for producing secreted proteins.
- the present invention provides pharmaceutical preparations and methods for controlling the proliferation of epithelially-derived tissue utilizing, as an active ingredient, a telomerase-activating therapeutic agent.
- the invention also relates to methods of controlling proliferation of epithelial-derived tissue by use of the pharmaceutical preparations of the invention.
- a telomerase-activating therapeutic agent of the present invention may be used as part of regimens in the treatment of disorders of, or surgical or cosmetic repair of, such epithelial tissues as skin and skin organs; corneal, lens and other ocular tissue; mucosal membranes; and periodontal epithelium.
- the methods and compositions disclosed herein provide for the treatment or prevention of a variety of damaged epithelial and mucosal tissues.
- the subject method can be used to control wound healing processes, as for example may be desirable in connection with any surgery involving epithelial tissue, such as from dermatological or periodontal surgeries.
- exemplary surgical repair for which use of a telomerase-activating therapeutic agent is a candidate treatment include severe burn and skin regeneration, skin grafts, pressure sores, dermal ulcers, fissures, post surgery scar reduction, and ulcerative colitis.
- telomerase-activating therapeutic agents can be used to effect the growth of hair, as for example in the treatment of alopecia whereby hair growth is potentiated or otherwise extended.
- Still another aspect of the present invention provides a method of extending the lifetime of epithelial tissue in tissue culture.
- epidermal refers to the cellular covering of internal and external body surfaces (cutaneous, mucous and serous), including the glands and other structures derived therefrom, e.g., corneal, esophegeal, epidermal, and hair follicle epithelial cells.
- epithlelial tissue includes: olfactory epithelium, which is the pseudostratified epithelium lining the olfactory region of the nasal cavity, and containing the receptors for the sense of smell; glandular epithelium, which refers to epithelium composed of secreting cells; squamous epithelium, which refers to epithelium composed of flattened plate-like cells.
- epithelium can also refer to transitional epithelium, which that characteristically found lining hollow organs that are subject to great mechanical change due to contraction and distention, e.g. tissue which represents a transition between stratified squamous and columnar epithelium.
- epithelialization refers to healing by the growth of epithelial tissue over a denuded surface.
- skin refers to the outer protective covering of the body, consisting of the corium and the epidermis, and is understood to include sweat and sebaceous glands, as well as hair follicle structures.
- skin refers to the outer protective covering of the body, consisting of the corium and the epidermis, and is understood to include sweat and sebaceous glands, as well as hair follicle structures.
- the adjective “cutaneous” may be used, and should be understood to refer generally to attributes of the skin, as appropriate to the context in which they are used.
- the term "epidermis” refers to the outermost and nonvascular layer of the skin, derived from the embryonic ectoderm, varying in thickness from 0.07-1.4 mm. On the palmar and plantar surfaces it comprises, from within outward, five layers: basal layer composed of columnar cells arranged perpendicularly; prickle-cell or spinous layer composed of flattened polyhedral cells with short processes or spines; granular layer composed of flattened granular cells; clear layer composed of several layers of clear, transparent cells in which the nuclei are indistinct or absent; and horny layer composed of flattened, cornified non-nucleated cells. In the epidermis of the general body surface, the clear layer is usually absent.
- the "corium” or "dermis” refers to the layer of the skin deep to the epidermis, consisting of a dense bed of vascular connective tissue, and containing the nerves and terminal organs of sensation.
- the hair roots, and sebaceous and sweat glands are structures of the epidermis which are deeply embedded in the dermis.
- the term "hair” refers to a threadlike structure, especially the specialized epidermal structure composed of keratin and developing from a papilla sunk in the corium, produced only by mammals and characteristic of that group of animals. Also, the aggregate of such hairs.
- hair follicle refers to one of the tubular-invaginations of the epidermis enclosing the hairs, and from which the hairs grow; and "hair follicle epithelial cells” refers to epithelial cells which surround the dermal papilla in the hair follicle, e.g., stem cells, outer root sheath cells, matrix cells, and inner root sheath cells. Such cells may be normal non-malignant cells, or transformed/immortalized cells.
- Excisional wounds include tears, abrasions, cuts, punctures or lacerations in the epithelial layer of the skin and may extend into the dermal layer and even into subcutaneous fat and beyond. Excisional wounds can result from surgical procedures or from accidental penetration of the skin.
- “Burn wounds” refer to cases where large surface areas of skin have been removed or lost from an individual due to heat and/or chemical agents.
- Dermat skin ulcers refer to lesions on the skin caused by superficial loss of tissue, usually with inflammation. Dermal skin ulcers which can be treated by the method of the present invention include decubitus ulcers, diabetic ulcers, venous stasis ulcers and arterial ulcers.
- Decubitus wounds refer to chronic ulcers that result from pressure applied to areas of the skin for extended periods of time. Wounds of this type are often called bedsores or pressure sores.
- Venous stasis ulcers result from the stagnation of blood or other fluids from defective veins.
- Arterial ulcers refer to necrotic skin in the area around arteries having poor blood flow.
- Deep tissue refers to tissue in the mouth which is similar to epithelial tissue, for example gum tissue.
- the method of the present invention is useful for treating periodontal disease.
- Internal epithelial tissue refers to tissue inside the body which has characteristics similar to the epidermal layer in the skin. Examples include the lining of the intestine. The method of the present invention is useful for promoting the healing of certain internal wounds, for example wounds resulting from surgery.
- a "wound to eye tissue” refers to severe dry eye syndrome, corneal ulcers and abrasions and ophthalmic surgical wounds.
- the subject method has wide applicability to the treatment or prophylaxis of disorders afflicting epithelial tissue, as well as in cosmetic uses.
- the method can be characterized as including a step of contacting a cell, in vitro or in vivo, with an amount of an telomerase-activating therapeutic agent agent sufficient to alter the life span of the treated epithelial tissue.
- the mode of administration and dosage regimens will vary depending on the epithelial tissue(s) which is to be treated.
- topical formulations will be preferred where the treated tissue is epidermal tissue, such as dermal or mucosal tissues.
- a method which "promotes the healing of a wound” results in the wound healing more quickly as a result of the treatment than a similar wound heals in the absence of the treatment.
- “Promotion of wound healing” can also mean that the method causes the extends the proliferative and growth phase of, inter alia, keratinocytes, or that the wound heals with less scarring, less wound contraction, less collagen deposition and more superficial surface area.
- “promotion of wound healing” can also mean that certain methods of wound healing have improved success rates, (e.g. the take rates of skin grafts,) when used together with the method of the present invention.
- telomerase-activating therapeutic agent agents of the present invention can also be applied prophylactically, such as in the form of a cosmetic preparation, to enhance tissue regeneration processes, e.g., of the skin, hair and/or fingernails.
- Full and partial thickness burns are an example of a wound type which often covers large surface areas and therefore requires prolonged periods of time to heal. As a result, life- threatening complications such as infection and loss of bodily fluids often arise. In addition, healing in burns is often disorderly, resulting in scarring and disfigurement. In some cases wound contraction due to excessive collagen deposition results in reduced mobility of muscles in the vicinity of the wound.
- the compositions and method of the present invention can be used to enhance the healing of burns and to promote healing processes that result in more desirable cosmetic outcomes and less wound contraction and scarring. Severe burns which cover large areas are often treated by skin autografts taken from undamaged areas of the patient's body. The subject method can also be used in conjunction with skin grafts to impove the grafts performance and life span in culture, as well as improve the
- Dermal ulcers are yet another example of wounds that are amenable to treatment by the subject method, e.g., to cause healing of the ulcer and/or to prevent the ulcer from becoming a chronic wound.
- one in seven individuals with diabetes develop dermal ulcers on their extremities, which are susceptible to infection.
- Individuals with infected diabetic ulcers often require hospitalization, intensive services, expensive antibiotics, and, in some cases, amputation.
- Dermal ulcers such as those resulting from venous disease (venous stasis ulcers), excessive pressure (decubitus ulcers) and arterial ulcers also resist healing.
- the prior art treatments are generally limited to keeping the wound protected, free of infection and, in some cases, to restore blood flow by vascular surgery.
- the afflicted area of skin can be treated by a therapy which includes a telomerase-activating therapeutic agent agent which promotes epithelization of the wound, e.g., accelerates the rate of the healing of the skin ulcers.
- a therapy which includes a telomerase-activating therapeutic agent agent which promotes epithelization of the wound, e.g., accelerates the rate of the healing of the skin ulcers.
- the subject method is provided for treating or preventing gastrointestinal diseases.
- diseases are associated with disruption of the gastrointestinal epithelium or villi, including chemotherapy- and radiation- therapy-induced enteritis (i.e. gut toxicity) and mucositis, peptic ulcer disease, gastroenteritis and colitis, villus atrophic disorders, and the like.
- chemotherapy- and radiation- therapy-induced enteritis i.e. gut toxicity
- mucositis i.e. gut toxicity
- mucositis peptic ulcer disease
- gastroenteritis and colitis gastroenteritis and colitis
- villus atrophic disorders and the like.
- chemotherapeutic agents and radiation therapy used in bone marrow transplantation and cancer therapy affect rapidly proliferating cells in both the hematopoietic tissues and small intestine, leading to severe and often dose-limiting toxicities. Damage to the small intestine mucosal barrier results in serious complications of bleeding and sepsis.
- the subject method can be used to promote proliferation of gastrointenstinal epithelium and thereby increase the tolerated doses for radiation and chemotherapy agents.
- Effective treatment of gastrointestinal diseases may be determined by several criteria, including an enteritis score, other tests well known in the art.
- enteritis score other tests well known in the art.
- the epidermis thins and the skin appendages atrophy. Hair becomes sparse and sebaceous secretions decrease, with consequent susceptibility to dryness, chapping, and Assuring.
- the dermis diminishes with loss of elastic and collagen fibers.
- keratinocyte proliferation (which is indicative of skin thickness and skin proliferative capacity) decreases with age.
- telomerase-activating therapeutic agent can be used either therapeutically or cosmetically to counteract, at least for a time, the effects of aging on skin.
- the subject method can also be used in treatment of a wound to eye tissue.
- damage to corneal tissue may affect epithelial and/or endothelial cells, depending on the nature of the wound.
- Corneal epithelial cells are the non- keratinized epithelial cells lining the external surface of the cornea and provide a protective barrier against the external environment.
- Corneal wound healing has been of concern to both clinicians and researchers.
- Opthomologists are frequently confronted with corneal dystrophies and problematic injuries that result in persistent and recurrent epithelial erosion, often leading to permanent endothelial loss.
- the use of telomerase-activating therapeutic agents can be used in these instances to promote epithelialization of the affected corneal tissue.
- corneal epithelium is contacted with an amount of a telomerase-activating therapeutic agent effective to enhance proliferation of the corneal epithelial cells to appropriately heal the wound.
- Tissue replacement therapy is well established in the treatment of human disease. For example, more than 40,000 corneal transplants were performed in the United States in 1996.
- Human epidermal cells can be grown in vitro and used to populate burn sites and chronic skin ulcers and other dermal wounds.
- the subject method can be used to enhance the life span of epithelial tissue in vitro, as well as to enhance the grafting of the cultured epithelial tissue to an animal host
- the present method can be used for improving the "take rate" of a skin graft. Grafts of epidermal tissue can, if the take rate of the graft is to long, blister and shear, decreasing the likelihood that the autograft will "take", i.e.
- Take rates can be increased by the subject method by enhancing the proliferation of the keratinocytes.
- the method of increasing take rates comprises contacting the skin autograft with an effective wound healing amount of a telomerase-activating therapeutic agent described in the method of promoting wound healing and in the method of promoting the growth and proliferation of keratinocytes, as described above.
- Skin equivalents have many uses not only as a replacement for human or animal skin for skin grafting, but also as test skin for determining the effects of pharmaceutical substances and cosmetics on skin.
- a major difficulty in pharmacological, chemical and cosmetic testing is the difficulties in determining the efficacy and safety of the products on skin.
- One advantage of the skin equivalents of the invention is their use as an indicator of the effects produced by such substances through in vitro testing on test skin.
- the subject method can be used as part of a protocol for skin grafting of, e.g., denuded areas, granulating wounds and burns.
- telomerase-activating therapeutic agents can enhance such grafting techniques as split thickness autografts and epidermal autografts (cultured autogenic keratinocytes) and epidermal allografts (cultured allogenic keratinocytes).
- the use of the subject method to enhance the formation of skin equivalents in culture helps to provide/maintain a ready supply of such grafts (e.g., in tissue banks) so that the patients might be covered in a single procedure with a material which allows permanent healing to occur.
- the present invention also concerns composite living skin equivalents comprising an epidermal layer of cultured keratinocyte cells which have been expanded in the presence of a telomerase-activating therapeutic agent.
- the subject method can be used as part of a process for the preparation of composite living skin equivalents.
- such a method comprises obtaining a skin sample, treating the skin sample enzymically to separate the epidermis from the dermis, treating the epidermis enzymically to release the keratinocyte cells, culturing, in the presence of a telomerase-activating therapeutic agent, the epidermal keratinocytes until confluence, in parallel, or separately, treating the dermis enzymatically to release the fibroblast cells, culturing the fibroblasts cells until sub-confluence, inoculating a porous, cross-linked collagen sponge membrane with the cultured fibroblast cells, incubating the inoculated collagen sponge on its surface to allow the growth of the fibroblast cells throughout the collagen sponge, and then inoculating it with cultured keratinocyte cells, and further incubating the composite skin equivalent complex in the presence of a telomerase- activating therapeutic agent to enhance the life span of the cells.
- skin sheets containing both epithelial and mesenchymal layers can be isolated in culture and expanded with culture media supplemented with a telomerase- activating therapeutic agent.
- Any skin sample amenable to cell culture techniques can be used in accordance with the present invention.
- the skin samples may be autogenic or allogenic.
- the subject method can be used in conjunction with various periodontal procedures in which control of epithelial cell proliferation in and around periodontal tissue is desired.
- proliferative forms of the hedgehog and ptc therapeutics can be used to enhance reepithelialization around natural and prosthetic teeth, e.g., to promote formation of gum tissue.
- the subject method can be used to help control guided tissue regeneration, such as when used in conjunction with bioresorptable materials.
- incorporation of periodontal implants, such as prosthetic teeth can be facilitated by the instant method.
- Reattachment of a tooth involves both formation of connective tissue fibers and re- epithelization of the tooth pocket.
- the subject method treatment can be used to enhance tissue reattachment by controlling the mitotic capacity of basal epithelial cells in the wound healing process.
- telomere maintenance has been proposed as an essential prerequisite to human tumor development.
- the telomerase enzyme is itself a specific marker for tumor cells, but the genetic alterations that activate the enzyme during neoplastic tranformation have remained a mystery.
- Amplification of the myc oncogene is prevalent in a broad spectrum of human tumors.
- myc induces telomerase both in normal human mammary epithelial cells (HMEC) and in normal human diploid fibroblasts.
- HMEC normal human mammary epithelial cells
- Myc increases expression of hEST2 (hEST/TP2), the catalytic subunit of telomerase. Since hEST2 limits enzyme activity in normal cells, myc may control telomerase solely by regulating hEST2 levels.
- telomere length is sufficient to increase average telomere length and extend lifespan in normal human mammary epithelial cells. Since myc can also extend the lifespan of these cells, activation of telomerase may be one mechanism by which myc contributes to tumor formation.
- Telomerase activity is largely absent from somatic cells in vivo and from normal human cells in culture 1. As these cells proliferate, telomeric repeats are progressively lost due to the incomplete replication of chromosome ends during each division cycle 2-5 Telomere shortening has been proposed as the mitotic clock that marks the progress of a cell toward the end of its replicative life-span. According to this model, erosion of chromosome ends triggers cellular senescence ° ⁇ Bypass of senescence through negation of tumor suppressor pathways (e.g. p53 and Rb/pl6) allows continued proliferation and further loss of telomeric sequences ->.
- tumor suppressor pathways e.g. p53 and Rb/pl6
- telomere loss Indefinite proliferation in the absence of telomere maintenance would result in chromosomal destabilization due to complete loss of telomeres ⁇ . Since this is probably incompatible with survival, cells with an indeterminate life span must adopt strategies for telomere conservation 1 > 9, 10.
- telomere maintenance might be an essential component of the tumorigenic phenotype led us to survey known oncogenes for the ability to activate the telomerase enzyme.
- HMEC- 16 E6 protein stimulates telomerase activity, suggesting that, in these cells, a single genetic event can potentiate the enzyme 16, 17 (pjg 3) HMEC were therefore used for the oncogene survey.
- Ectopic expression of mdm-2 failed to induce telomerase, consistent with the observation that activation of telomerase by E6 is separable from the ability of E6 to promote the degradation of p53 ⁇ (data not shown).
- telomere activity was detectable within one passage after transduction of HMEC with a retrovirus that directs myc expression.
- the myc-expressing population contained levels of telomerase activity that approximated those seen in a random sample of breast carcinoma cell lines (Fig. 3; e. g. T47D).
- E6 into normal human diploid fibroblasts fails to activate telomerase 16, (Fig.
- telomerase was induced by transduction of either IMR-90 (Fig. 4) or WI-38 cells (not shown) with a retrovirus that directs myc expression. As with HMEC, activity was apparent immediately after infection, and following selection of the myc-expressing population, telomerase reached levels comparable to those seen in a telomerase-positive fibrosarcoma cell line, HT1080 (Fig. 4).
- telomere activity The presence of the mRNA encoding hEST2, the catalytic subunit of telomerase, strictly correlates with telomerase activity.
- the mRNA for hEST2 is undetectable in normal tissue and in normal cell lines, whereas hEST2 is present in immortal and tumor-derived cell lines 19-21 Moreover, hEST2 expression and telomerase are concomitantly suppressed when cells are induced to differentiate 20 As expected, hEST2 mRNA was absent from normal HMEC. However, hEST2 could be detected in HMEC cells following transduction with a myc retrovirus (Fig. 6A).
- telomere a transcription factor that can enhance the expression of responsive genes.
- myc could increase hEST2 expression by directly stimulating the hEST2 promoter.
- changes in hEST2 expression could arise as a secondary consequence of the ability of myc to regulate other genes.
- telomere length is regulated at two distinct levels. First, preservation of telomeric repeats requires either the telomerase enzyme or the activation of an alternative pathway for telomere maintenance 1, 9, 10, 14, 22 Second, telomere length can be controlled by telomere binding proteins 3. ⁇ 0 determine whether activation of telomerase in HMEC cells is sufficient to stabilize telomere length, we followed telomeric restriction fragment (TRF) size as HMEC were passaged either in the presence or absence of telomerase activity. In normal HMEC, telomere length diminished slightly as cells underwent multiple rounds of division (Fig. 6C).
- telomere length has been proposed as the counting mechanism that determines the replicative lifespan of a cell.
- hEST2 which recieved either hEST2 or myc expression cassettes display extended lifespan as compared to vector-transduced cells (Fig. 6D). This supports the notion that telomere length is one of the criteria used by a cell to calculate its proliferative capacity.
- ectopic expression of myc can induce telomerase both in normal epithelial cells and in normal fibroblasts and can extend the replicative lifespan of HMEC.
- the myc oncogene is activated by gene amplification and possibly by mutation in a wide variety of different tumor types 24, 25 Since myc can elevate telomerase to a level approximating that observed in tumor cell lines, increased myc activity could account for the presence of telomerase in many late-stage tumors. In this regard, a study of 100 neuroblastomas revealed that -20% (16/100) had exceptionally high telomerase activity. Of these, 11 showed amplification of the N-wyc locus 26 Thus, in this case, telomerase levels correlated well with myc activation. Although the myc oncogene may induce telomerase in significant proportion of tumors, the enzyme may also be regulated by other pathways 27.
- telomere maintenance may contribute to the long-term proliferative potential of tumor cells
- telomerase activation may be an essential component of the ability of myc to facilitate tumor formation.
- Retroviral plasmids The following viral plasmids were used for transfection: pBabe-puro 9 ⁇ MarXII-hygro, mouse c-wyc/MarXII-hygro (gifts from Dr. P. Sun, CSHL), E6/pBabe-puro, cdc25A/MarXII-hygro.
- the full length hEST2 cDNA (a gift from Dr. R. Weinberg) was cloned into pBabe-puro vector at the EcoRI and Sail sites.
- HMEC Human mammary epithelial cells
- IMR90 and WI38 normal human diploid fibroblasts
- BT549, T47D and HBL100 human breast cancer cell lines
- HT1080 cells were a gift from G. Stark (Cleveland Clinic Foundation).
- the amphotropic packaging line, linX-A was produced in our laboratory (L. Y. X, D. B. and G. H., unpublished).
- HMEC were cultured in complete MEGM (Clonetics).
- Fibroblasts and LinX- A cells were maitained in DMEM (GIBCO) plus 10% fetal bovine serum (FBS; Sigma). BT549, HBL100 and T47D were maintained as directed by the supplier. LinX-A cells were transfected by calcium-phosphate precipitation with a mixture containing 15 ⁇ g of retroviral plasmid and 15 ⁇ g of sonicated salmon sperm DNA. Transfected cells were incubated at 37°C for 24 hr and then shifted to 30°C for virus production. After 48 hr, the virus was collected, and the virus- containing medium was filtered to remove packaging cells (0.45 ⁇ m filter; Millipore).
- Target cells were infected with virus supernatants supplemented with 4 ⁇ g/ml polybrene (Sigma) by centrifuging for 1 hr at 1000 g and then incubating at 30°C overnight. The infected cells were selected 48 hours after infection using appropriate drugs (hygromycin, G418 or puro ycin).
- TRAP assays The TRAP assay was performed essentially as described 1 with some modification. Briefly, extracts were prepared in lysis buffer (10 mM Tris [pH 7.5], 1 mM MgCl2, 1 mM EGTA, 10% Glycerol), and cleared by centrifugation for 30 min at 50,000xg.
- Lysate corresponding to from 10 to 10 cells was used in the assay.
- Telomeric repeats were synthesized onto an oligonucleotide, TS (5' AATCCGTCGAGCAGAGTT3'), in an extension reaction that proceeded at 30°C for 1 hr. Extension products were amplified by polymerase chain reaction (PCR) in the presence of 32 P-dATP using TS in combination with a downstream anchor primer (5' GCGCGGCTAACCCTAACCCTAACC 3'). Five microliters of each reaction was analyzed on a 6% acrylamide / 8 M urea gel.
- Western blotting was performed essentially as described 30. Cells were washed with cold PBS and lysed in Laemmli loading buffer. Lysates were heated at 95°C for 10 min. Samples were separated on 8% SDS-PAGE gels and transferred to nitrocellulose membranes (Schleicher & Schuell). The blots were incubated either with a c-myc rabbit polyclonal antibody (N-262; Santa Crutz) or with a TFIIB rabbit polyclonal antibody (a gift from
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99903059A EP1045697A2 (en) | 1998-01-12 | 1999-01-12 | Extension of cellular lifespan, methods and reagents |
IL13710199A IL137101A0 (en) | 1998-01-12 | 1999-01-12 | Extension of cellular lifespan, methods and reagents |
CA002315265A CA2315265A1 (en) | 1998-01-12 | 1999-01-12 | Extension of cellular lifespan, methods and reagents |
JP2000527629A JP2002500040A (en) | 1998-01-12 | 1999-01-12 | Extending cell life, methods and reagents |
AU23172/99A AU759437B2 (en) | 1998-01-12 | 1999-01-12 | Extension of cellular lifespan, methods and reagents |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7122098P | 1998-01-12 | 1998-01-12 | |
US60/071,220 | 1998-01-12 | ||
US7145598P | 1998-01-13 | 1998-01-13 | |
US60/071,455 | 1998-01-13 | ||
US6365798A | 1998-04-21 | 1998-04-21 | |
US09/063,657 | 1998-04-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999035243A2 true WO1999035243A2 (en) | 1999-07-15 |
WO1999035243A3 WO1999035243A3 (en) | 1999-09-16 |
WO1999035243A9 WO1999035243A9 (en) | 1999-10-28 |
Family
ID=27370514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/000682 WO1999035243A2 (en) | 1998-01-12 | 1999-01-12 | Extension of cellular lifespan, methods and reagents |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1045697A2 (en) |
JP (1) | JP2002500040A (en) |
AU (1) | AU759437B2 (en) |
CA (1) | CA2315265A1 (en) |
IL (1) | IL137101A0 (en) |
WO (1) | WO1999035243A2 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023039A2 (en) * | 1998-10-16 | 2000-04-27 | Ensley Burt D | Recombinant hair treatment compositions |
WO2000031238A2 (en) * | 1998-11-25 | 2000-06-02 | Genetica, Inc. | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
WO2001011011A3 (en) * | 1999-08-05 | 2001-05-10 | Leo T Furcht | Multipotent adult stem cells and methods for isolation |
WO2001094556A1 (en) * | 2000-06-07 | 2001-12-13 | Neurotech | Method for conditionally immortalising cells and protein constructs therefor |
WO2002010352A2 (en) * | 2000-08-02 | 2002-02-07 | Whitehead Institute For Biomedical Research | Production of human monoclonal antibodies |
JP2003514565A (en) * | 1999-11-25 | 2003-04-22 | ユニヴェルシテ・ドゥ・ジュネーブ | Vector capable of immortalizing non-dividing cells and cells immortalized with said vector |
WO2003066839A1 (en) * | 2002-02-05 | 2003-08-14 | Rappaport Family Institute For Research In The Medical Sciences | Lineage committed stem cells selected for telomerase promoter activity |
US6686159B2 (en) | 2000-08-24 | 2004-02-03 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US7211435B2 (en) | 2001-06-21 | 2007-05-01 | Sierra Sciences, Inc. | Telomerase expression repressor proteins and methods of using the same |
US7838289B2 (en) | 2001-02-14 | 2010-11-23 | Abt Holding Company | Assay utilizing multipotent adult stem cells |
WO2010135247A1 (en) | 2009-05-18 | 2010-11-25 | TA Therapeutics, Ltd. | Compositions and methods for increasing telomerase activity |
US7846904B2 (en) | 2003-06-23 | 2010-12-07 | Geron Corporation | Compositions and methods for increasing telomerase activity |
AU2006202072B2 (en) * | 1999-08-05 | 2010-12-09 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
EP2402038A1 (en) * | 2010-07-02 | 2012-01-04 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Telomerase reverse transcriptase for protection against ageing |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US8409859B2 (en) | 2005-10-14 | 2013-04-02 | Regents Of The University Of Minnesota | Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
US8426200B2 (en) | 2003-07-02 | 2013-04-23 | Regents Of The University Of Minnesota | Neuronal differentiation of stem cells |
US8609412B2 (en) | 1999-08-05 | 2013-12-17 | Regents Of The University Of Minnesota | Mapc generation of lung tissue |
US8609406B2 (en) | 2010-08-24 | 2013-12-17 | Regents Of The University Of Minnesota | Non-static suspension culture of cell aggregates |
US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
US9057051B2 (en) | 2008-10-31 | 2015-06-16 | Katholieke Universiteit Leuven | Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells |
US9090878B2 (en) | 2010-06-17 | 2015-07-28 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
US9248088B2 (en) | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
US9464284B2 (en) | 2009-03-09 | 2016-10-11 | Bioatla, Llc | Mirac proteins |
US9764044B2 (en) | 2002-11-27 | 2017-09-19 | Abt Holding Company | Homologous recombination in multipotent adult progenitor cells |
US9861660B2 (en) | 2013-04-12 | 2018-01-09 | Saverio LaFrancesca | Organs for transplantation |
US9937208B2 (en) | 2010-05-12 | 2018-04-10 | Abt Holding Company | Modulation of splenocytes in cell therapy |
US10253297B2 (en) | 2008-01-18 | 2019-04-09 | Regents Of The University Of Minnesota | Stem cell aggregates and methods for making and using |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
CN114601747A (en) * | 2022-03-07 | 2022-06-10 | 广州市万千粉丝化妆品有限公司 | Application of nucleoprotein telomerase with functions of promoting growth of protein and RNA, prolonging cell telomere and proliferating in cosmetics |
CN114657281A (en) * | 2020-12-22 | 2022-06-24 | 中国科学院动物研究所 | Endogenous virus as marker of aging degree and application of endogenous virus as aging intervention target |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS59462B1 (en) | 2010-02-16 | 2019-11-29 | Ultimovacs As | Polypeptides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995013382A1 (en) * | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
WO1996040868A1 (en) * | 1995-06-07 | 1996-12-19 | Cold Spring Harbor Laboratory | Essential oligonucleotides of vertebrate telomerase |
US5830644A (en) * | 1992-05-13 | 1998-11-03 | Geron Corporation | Method for screening for agents which increase telomerase activity in a cell |
-
1999
- 1999-01-12 IL IL13710199A patent/IL137101A0/en unknown
- 1999-01-12 WO PCT/US1999/000682 patent/WO1999035243A2/en active IP Right Grant
- 1999-01-12 EP EP99903059A patent/EP1045697A2/en not_active Withdrawn
- 1999-01-12 AU AU23172/99A patent/AU759437B2/en not_active Ceased
- 1999-01-12 JP JP2000527629A patent/JP2002500040A/en not_active Withdrawn
- 1999-01-12 CA CA002315265A patent/CA2315265A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830644A (en) * | 1992-05-13 | 1998-11-03 | Geron Corporation | Method for screening for agents which increase telomerase activity in a cell |
WO1995013382A1 (en) * | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
WO1996040868A1 (en) * | 1995-06-07 | 1996-12-19 | Cold Spring Harbor Laboratory | Essential oligonucleotides of vertebrate telomerase |
Non-Patent Citations (6)
Title |
---|
AUTEXIER C ET AL: "RECONSTITUTION OF HUMAN TELOMERASE ACTIVITY AND IDENTIFICATION OF AMINIMAL FUNCTIONAL REGION OF THE HUMAN TELOMERASE RNA" EMBO JOURNAL, vol. 15, no. 21, 1 November 1996, pages 5928-5935, XP002056802 * |
H. VAZIRI AND S. BENCHIMOL: "RECONSTITUTION OF TELOMERASE ACTIVITY IN NORMAL HUMAN CELLS LEADS TO ELONGATION OF TELOMERES AND EXTENDED REPLICATIVE LIFE SPAN" CURRENT BIOLOGY, vol. 8, no. 5, 26 February 1998, pages 279-282, XP002107653 * |
J. WANG ET AL.: "MYC ACTIVATES TELOMERASE" GENES & DEVELOPMENT, vol. 12, 1998, pages 1769-1774, XP002107654 cited in the application * |
K. FUJIMOTO AND M. TAKAHASHI: "TELOMERASE ACTIVITY IN HUMAN LEUKEMIC CELL LINES IS INHIBITED BY ANTISENSE PENTADECADEOXYNUCLEOTIDES TARGETED AGAINST C-MYC MRNA" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 241, 1997, pages 775-781, XP002107655 * |
K. HIYAMA ET AL.: "ACTIVATION OF TELOMERASE IN HUMAN LYMPHOCYTES AND HEMATOPOIETIC PROGENITOR CELLS" J. IMMUNOLOGY, vol. 155, no. 8, 1995, pages 3711-3715, XP002107651 * |
S.L. WEINRICH ET AL.: "RECONSTITUTION OF HUMAN TELOMERASE WITH THE TEMPLATE RNA COMPONENT HTR AND THE CATALYTIC PROTEIN SUBUBIT HTRT" NATURE GENETICS, vol. 17, 1997, pages 498-502, XP002107652 cited in the application * |
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023039A2 (en) * | 1998-10-16 | 2000-04-27 | Ensley Burt D | Recombinant hair treatment compositions |
WO2000023039A3 (en) * | 1998-10-16 | 2000-07-27 | Burt D Ensley | Recombinant hair treatment compositions |
US6572845B2 (en) | 1998-10-16 | 2003-06-03 | Burt D. Ensley | Recombinant hair treatment compositions |
WO2000031238A2 (en) * | 1998-11-25 | 2000-06-02 | Genetica, Inc. | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
WO2000031238A3 (en) * | 1998-11-25 | 2000-11-09 | Genetica Inc | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
US7659118B2 (en) | 1999-08-05 | 2010-02-09 | Abt Holding Company | Multipotent adult stem cells |
AU2006202072B2 (en) * | 1999-08-05 | 2010-12-09 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
US8609412B2 (en) | 1999-08-05 | 2013-12-17 | Regents Of The University Of Minnesota | Mapc generation of lung tissue |
US10226485B2 (en) | 1999-08-05 | 2019-03-12 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
EP2348104A1 (en) * | 1999-08-05 | 2011-07-27 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
WO2001011011A3 (en) * | 1999-08-05 | 2001-05-10 | Leo T Furcht | Multipotent adult stem cells and methods for isolation |
US9974809B2 (en) | 1999-08-05 | 2018-05-22 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
US9974810B2 (en) | 1999-08-05 | 2018-05-22 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US10006004B2 (en) | 1999-08-05 | 2018-06-26 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
US9974811B2 (en) | 1999-08-05 | 2018-05-22 | Abt Holding Company | Multipotent adult stem cells and methods for isolation |
JP2003514565A (en) * | 1999-11-25 | 2003-04-22 | ユニヴェルシテ・ドゥ・ジュネーブ | Vector capable of immortalizing non-dividing cells and cells immortalized with said vector |
FR2810046A1 (en) * | 2000-06-07 | 2001-12-14 | Neurotech | Preparing conditionally immortalized cells, useful e.g. for cellular therapy and screening, by treatment with immortalizing proteins |
WO2001094556A1 (en) * | 2000-06-07 | 2001-12-13 | Neurotech | Method for conditionally immortalising cells and protein constructs therefor |
WO2002010352A2 (en) * | 2000-08-02 | 2002-02-07 | Whitehead Institute For Biomedical Research | Production of human monoclonal antibodies |
WO2002010352A3 (en) * | 2000-08-02 | 2003-02-27 | Whitehead Biomedical Inst | Production of human monoclonal antibodies |
US6686159B2 (en) | 2000-08-24 | 2004-02-03 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression |
US7838289B2 (en) | 2001-02-14 | 2010-11-23 | Abt Holding Company | Assay utilizing multipotent adult stem cells |
US7795416B2 (en) | 2001-06-21 | 2010-09-14 | Sierra Sciences Inc. | Telomerase expression repressor proteins and methods of using the same |
US7211435B2 (en) | 2001-06-21 | 2007-05-01 | Sierra Sciences, Inc. | Telomerase expression repressor proteins and methods of using the same |
WO2003066839A1 (en) * | 2002-02-05 | 2003-08-14 | Rappaport Family Institute For Research In The Medical Sciences | Lineage committed stem cells selected for telomerase promoter activity |
US10583202B2 (en) | 2002-11-27 | 2020-03-10 | Abt Holding Company | Homologous recombination in multipotent adult progenitor cells |
US9764044B2 (en) | 2002-11-27 | 2017-09-19 | Abt Holding Company | Homologous recombination in multipotent adult progenitor cells |
US8759304B2 (en) | 2003-06-23 | 2014-06-24 | Telomerase Activation Science, Inc. | Compositions and methods for increasing telomerase activity |
US7846904B2 (en) | 2003-06-23 | 2010-12-07 | Geron Corporation | Compositions and methods for increasing telomerase activity |
EP2548880A2 (en) | 2003-06-23 | 2013-01-23 | Geron Corporation | Compositions for increasing telomerase activity |
US9248088B2 (en) | 2003-06-25 | 2016-02-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for skin conditioning |
US8426200B2 (en) | 2003-07-02 | 2013-04-23 | Regents Of The University Of Minnesota | Neuronal differentiation of stem cells |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US8409859B2 (en) | 2005-10-14 | 2013-04-02 | Regents Of The University Of Minnesota | Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype |
US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
US10253297B2 (en) | 2008-01-18 | 2019-04-09 | Regents Of The University Of Minnesota | Stem cell aggregates and methods for making and using |
US10457914B2 (en) | 2008-10-31 | 2019-10-29 | Katholieke Universiteit Leuven | Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells |
US9057051B2 (en) | 2008-10-31 | 2015-06-16 | Katholieke Universiteit Leuven | Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells |
US9982252B2 (en) | 2009-03-09 | 2018-05-29 | Bioatla, Llc | Mirac proteins |
US9637734B2 (en) | 2009-03-09 | 2017-05-02 | Bioatla, Llc | Mirac proteins |
US9464284B2 (en) | 2009-03-09 | 2016-10-11 | Bioatla, Llc | Mirac proteins |
US11718844B2 (en) | 2009-03-09 | 2023-08-08 | Bioatla, Inc. | Mirac proteins |
US9637735B2 (en) | 2009-03-09 | 2017-05-02 | Bioatla, Llc | Mirac proteins |
US9994841B2 (en) | 2009-03-09 | 2018-06-12 | Bioatla, Llc | Mirac proteins |
US9913851B2 (en) | 2009-05-18 | 2018-03-13 | Telomerase Activation Sciences, Inc. | Compositions and methods for increasing telomerase activity |
US9403866B2 (en) | 2009-05-18 | 2016-08-02 | Telomerase Activation Sciences, Inc. | Compositions and methods for increasing telomerase activity |
US8481721B2 (en) | 2009-05-18 | 2013-07-09 | Telomerase Activation Sciences, Inc. | Compositions and methods for increasing telomerase activity |
WO2010135247A1 (en) | 2009-05-18 | 2010-11-25 | TA Therapeutics, Ltd. | Compositions and methods for increasing telomerase activity |
US9937208B2 (en) | 2010-05-12 | 2018-04-10 | Abt Holding Company | Modulation of splenocytes in cell therapy |
US10758570B2 (en) | 2010-05-12 | 2020-09-01 | Abt Holding Company | Modulation of splenocytes in cell therapy |
US9090878B2 (en) | 2010-06-17 | 2015-07-28 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
US9777258B2 (en) | 2010-06-17 | 2017-10-03 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the method, and methods for using the cells |
EP2402038A1 (en) * | 2010-07-02 | 2012-01-04 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Telomerase reverse transcriptase for protection against ageing |
WO2012001170A1 (en) * | 2010-07-02 | 2012-01-05 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Telomerase reverse transcriptase for protection against ageing |
US8609406B2 (en) | 2010-08-24 | 2013-12-17 | Regents Of The University Of Minnesota | Non-static suspension culture of cell aggregates |
US9447380B2 (en) | 2010-08-24 | 2016-09-20 | Regents Of The University Of Minnesota | Non-static suspension culture of cell aggregates |
US9861660B2 (en) | 2013-04-12 | 2018-01-09 | Saverio LaFrancesca | Organs for transplantation |
US11071752B2 (en) | 2013-04-12 | 2021-07-27 | Abt Holding Company | Organs for transplantation |
CN114657281A (en) * | 2020-12-22 | 2022-06-24 | 中国科学院动物研究所 | Endogenous virus as marker of aging degree and application of endogenous virus as aging intervention target |
CN114601747A (en) * | 2022-03-07 | 2022-06-10 | 广州市万千粉丝化妆品有限公司 | Application of nucleoprotein telomerase with functions of promoting growth of protein and RNA, prolonging cell telomere and proliferating in cosmetics |
Also Published As
Publication number | Publication date |
---|---|
IL137101A0 (en) | 2001-06-14 |
JP2002500040A (en) | 2002-01-08 |
WO1999035243A3 (en) | 1999-09-16 |
CA2315265A1 (en) | 1999-07-15 |
AU759437B2 (en) | 2003-04-17 |
EP1045697A2 (en) | 2000-10-25 |
AU2317299A (en) | 1999-07-26 |
WO1999035243A9 (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU759437B2 (en) | Extension of cellular lifespan, methods and reagents | |
EP1133552A2 (en) | Methods and reagents for increasing proliferative capacity and preventing replicative senescence | |
US5958769A (en) | Compositions and methods for mediating cell cycle progression | |
AU2001264598B2 (en) | Compositions and methods for tissue dedifferentiation and regeneration | |
AU2003300794A1 (en) | Compositions and methods for cell dedifferentiation and tissue regeneration | |
US6177272B1 (en) | Method for treating vascular proliferative diseases with p27 and fusions thereof | |
AU2001264598A1 (en) | Compositions and methods for tissue dedifferentiation and regeneration | |
JP5802195B2 (en) | Compositions and methods for modulating stem cells and uses thereof | |
Wu et al. | SIRT1 activation promotes β-cell regeneration by activating endocrine progenitor cells via AMPK signaling-mediated fatty acid oxidation | |
AU2016264166A1 (en) | Method for inducing oligodendrocyte precursor cells from Oct4-induced human somatic cells through direct reprogramming | |
KR101169980B1 (en) | Method of growing myocardial cells | |
AU760252B2 (en) | Modulation of cell proliferation, methods and reagents | |
WO2020065080A2 (en) | Long non-coding rna h19 for use in treatment of ischemic acute kidney injury | |
US7732206B2 (en) | Oligodendrocyte determination genes and uses thereof | |
EP3259346A1 (en) | P63 inactivation for the treatment of heart failure | |
WO2018183653A1 (en) | Method of generating and using cd34+ cells derived from fibroblasts | |
CA2447703C (en) | Methods for proliferating terminal differentiated cells and recombinant vectors therefor | |
US7795032B2 (en) | Methods for proliferating cardiomyocytes and recombinant vectors therefor | |
WO2001048149A1 (en) | Adult bone marrow-origin cell capable of differentiating into heart muscle cell | |
CA3216719A1 (en) | Methods of generating mature corneal endothelial cells | |
JP5804545B2 (en) | Embryoid body differentiation regulator | |
DiGirolamo | The potential of human bone marrow stromal cells as vehicles for ex vivo gene therapy applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 137101 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2315265 Country of ref document: CA Ref country code: CA Ref document number: 2315265 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 23172/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999903059 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 527629 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999903059 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999903059 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 23172/99 Country of ref document: AU |